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BH4 tetrahydrobiopterin
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CNS central nervous system
CSF cerebrospinal fluid
ECT electroconvulsive therapy
GABA gamma-aminobutyric acid
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Depression
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HPLC high performance liquid
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NO nitric oxide
NOS nitric oxide synthase
Phe phenylalanine
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SCN suprachiasmatic nucleus
Trp tryptophan
Tyr tyrosine
YMRS Young Mania Rating Scale
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Introduction
11. Introduction
After centuries with various ideas about the pathophysiological mechanisms of
'µελανøïλια' (melancholia, from the Greek, 'black bile'), in the 1950's, neurochemical
hypotheses of mood disturbances emerged after the development of antidepressants
(Lehmann and Kline, 1983; Wong and Licinio, 2001). The first idea on the biochemical
pathophysiology of depression was the so-called monoamine hypothesis (Schildkraut,
1965). Based on this hypothesis, the selective serotonin reuptake inhibitors were
developed. Over the past decades, it has become obvious that alterations in monoamines
are most probably related to an overdrive of the HPA-axis, induced e.g. by stress (Holsboer,
1995; Dinan, 1995; De Kloet et al., 1996; De Kloet et al., 1998). 
Early neurochemical explanations of bipolar disorders have implicated catecholamines and
other neurotransmitters like serotonin, acetylcholine and GABA. More recent hypotheses
deal with intracellular signaling cascades (Anand and Charney, 2000; Massat et al., 2000;
Manji et al., 2001; Kugaya and Sanacora, 2005).  
Despite extensive research, however, biochemical abnormalities underlying the predispo-
sition to and the pathophysiology of affective disorders have so far not clearly been
elucidated. Another area of research focuses on the role of pterins in affective disorders.
Pterins (also called pteridines) are derived from guanosine triphosphate (GTP) and these
compounds are important for the metabolism of monoamines and the biosynthesis of the
reactive free radical nitric oxide (NO) (Mayer and Werner, 1995; van Amsterdam and
Opperhuizen, 1999; Koshimura et al., 2000). 
In the next paragraphs the biosynthesis, localization and clinical relevance of pterins and
NO will be concisely described.
2. Biosynthesis of pterins
Pterins are compounds containing a 2-amino-4-oxo-pyrazine-pyrimidine (pterin) ring,
which are derived from GTP via a magnesium-dependent cyclohydrolase (Nichol et al.,
1985). GTP is converted to dihydroneopterin triphosphate and this substance can be
converted to either neopterin or tetrahydrobiopterin (BH4) (Fig. 1). Neopterin is
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synthesized primarily by human monocytes and macrophages after stimulation by
interferon-gamma produced by helper T-cells (Huber et al., 1984). BH4 is the essential
cofactor for the hydroxylation of phenylalanine to tyrosine, tyrosine to L-3,4-dihydro-
xyphenylanine (L-DOPA) and tryptophan to 5-hydroxytryptophan. The latter two reactions
are rate-limiting steps in the synthesis of the catecholamines and serotonin, respectively.
During these reactions, BH4 is transformed to quinoid dihydrobiopterin via pterin-4a-
carbinolamine (Fig. 1). Concentrations of BH4 are maintained by de novo synthesis and by
a salvage mechanism that reduces quinoid dihydrobiopterin back to BH4. BH4 is secreted
in the urine together with its oxidative products dihydrobiopterin and biopterin (Levine,
1988; Auerbach and Nar, 1997; Thöny et al, 2000). Synthesis of BH4 is not dependent on
dietary pterin, which is poorly absorbed from the gut (Leeming, 1980).
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Figure 1. 
Biosynthesis and function of tetrahydrobiopterin.
GTP = guanosine triphosphate
GTPCH = guanosine triphosphate cyclohydrolase
DHPR = dihydropterine reductase
PAH = phenylalanine hydroxylase
TH = tyrosine hydroxylase
TPH = tryptophan hydroxylase
NOS = nitric oxide synthase
L-DOPA = L-3,4-dihydroxyphenylanine 
5-OH trp = 5-hydroxytryptophan
NO = nitric oxide
The reaction catalyzed by GTPCH is the rate-limiting step in the
synthesis of tetrahydrobiopterin. Tetrahydrobiopterin is cofactor
for the enzymatic reactions in the 4 squares. The cursive com-
pounds are the excretion products of the pterin metabolism.
Total biopterin is biopterin, q-dihydrobiopterin together with
tetrahydrobiopterin.
Ï
Ï
3. Localization of pterins
BH4 is present in the liver, the gastrointestinal tract, the adrenal medulla, T-lymphocytes
and macrophages. Brain areas like hypothalamus, pituitary gland and pineal gland contain
relatively large concentrations of BH4 (Bullard et al., 1978; Levine, 1988; Thöny et al.,
2000; Koshimura et al., 2000). Pterins are functionally closely related to the cellular
immune system. Interferon-gamma, which is produced and secreted by activated T-
lymphocytes, stimulates GTP cyclohydrolase activity, resulting in synthesis of neopterin in
macrophages. Neopterin is therefore regarded as a validated marker of the activation of
cell-mediated immunity (Dunbar et al., 1992; Maes et al., 1994; Matsuda et al., 1994;
Bonaccorso et al, 1998). The close relationship between the cellular immune system and
the HPA-axis, suggests a role of the pterins in stress related disorders, like depression. 
4. BH4 metabolism and monoamines
BH4 is the natural cofactor of the aromatic amino acid hydroxylating enzymes tryptophan
hydroxylase and tyrosine hydroxylase. The reactions catalyzed by these enzymes are the
rate limiting steps in the formation of serotonin and the catecholamines dopamine and
norepinephrine, respectively (Fig. 1.). Several in vitro studies showed that administration of
BH4 results in an increased release of dopamine and serotonin as well as of glutamate
(Miwa et al., 1985; Koshimura et al., 1990; Wolf et al., 1991). Independent of its role as a
cofactor, BH4 seems to have a direct influence on the release mechanisms of these
neurotransmitters (Mataga et al., 1991; Muguruma et al., 1996).
The essential role of BH4 in the synthesis of neurotransmitters is illustrated by congenital
BH4 deficiencies. A disturbed BH4 synthesis causes atypical phenylketonuria (Pogson,
1997). About 2% of patients with phenylketonuria show a BH4-deficiency (Blau et al.,
1996). In patients with congenital biopterin deficiency, decreased plasma and
cerebrospinal fluid (CSF) concentrations of serotonin, dopamine and their metabolites
were found next to hyperphenylalaninemia (Kaufman, 1998; Pogson, 1997). Without
substitution this leads to severe neurological and psychiatric symptoms (Blaskovics and
Giudici, 1988; Kaufman, 1998; Pogson, 1997).
5. Pterins and affective disorders
The relationship between pterins and affective disorders has been studied since the 1980's
(Curtius et al., 1983; Levine and Lovenberg, 1984; Blair et al., 1984). This research strategy
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was given impetus since it appeared that these compounds influence the synthesis and
release of serotonin, dopamine and norepinephrine (Levine, 1988). Subsequent studies
investigated the relationship between pterins and nitric oxide (NO) (Mayer and Werner,
1995; van Amsterdam and Opperhuizen, 1999). 
5.1 Biochemical studies
As can be inferred from figure 1, the main product in the pterin synthesis is tetrahydro-
biopterin (BH4), which is an essential cofactor for several enzymatic processes (Levine,
1988). Along with BH4, neopterin is synthesized from the same precursor. In this respect,
several biochemical parameters have been studied of which BH4, total biopterin (the sum
of BH4, dihydrobiopterin and biopterin) and neopterin are the most relevant (Hashimoto
et al., 1987; Dunbar et al., 1992; Hashimoto et al., 1994). As indirect parameters of BH4
activity, the neopterin-biopterin ratio and/or the phenylalanine-tyrosine ratio are used
(Coppen et al, 1989; Anderson et al., 1992; Anderson et al., 1994; Abou-Saleh et al.,
1995). Measurements have been done in brain tissue, urine, plasma, serum and CSF. The
equivocal results of these studies are depicted in table 1. In most studies an increase of
total biopterin was found in depressed patients, whereas the activity of the active BH4
was decreased. The increased neopterin levels as demonstrated in some studies point
towards an activation of cell-mediated immune activity (Dunbar et al., 1992; Maes et al.,
1994; Bonaccorso et al., 1998). 
5.2 Genetic studies 
As presented in table 1, some genetic studies have recently been performed in search for
mutations in the gene that codes for the enzyme guanosine triphosphate cyclohydrolase
(GTPCH), which forms the rate-limiting step in the biosynthesis of BH4. Interestingly, in
families with a polymorphism for this particular gene, there is an increased prevalence of
psychiatric disorders (Hahn et al., 2001; Kealey et al., 2005; Van Hove et al., 2006). 
5.3 Therapy with BH4
Sofar virtually no studies have been conducted using BH4 as a pharmacological agent.
Preliminary results from older studies suggest that oral administration of BH4 may have
some short lasting beneficial effects on symptoms of depression. (Curtius et al., 1982;
Curtius et al., 1983; Woggon et al., 1984; Fleischhacker et al., 1985).
 
6. BH4 metabolism and Nitric Oxide
Apart from its role as an essential cofactor in the biosynthesis of monoamines, BH4 is
required as an obligatory cofactor for the enzymatic conversion of L-arginine to L-citrulline,
with nitric oxide (NO) as concomitant product (Fig. 2) (Mayer and Werner, 1995). 
The enzyme responsible for the generation of NO is nitric oxide synthase (NOS). Three NOS
isoforms have been described: neuronal NOS (nNOS), endothelial NOS (eNOS) and
inducible NOS (iNOS) that are coded by three distinct genes (Mayer and Werner, 1995;
Prast and Philippu, 2001). 
Endothelium-derived NO plays a crucial role in vascular function and homeostasis. Vascular
NO production is almost exclusively attributable to the activity of eNOS and is involved in
the vascular blood flow. The enzyme iNOS plays a key role in inflammatory reactions (Akyol
et al., 2004; Bernstein et al., 2005). 
In the central nervous system (CNS) nNOS is the major NOS isoform that accounts for about
90% of the overall NO production. In the human brain the highest levels of nNOS are
measured in the substantia innominata, septal area, cerebellar cortex, nucleus accumbens,
hypothalamus and subthalamus. In the cerebral cortex, nNOS is localized in 2% of the
neurons, whereas in the human hypothalamic paraventricular nucleus, up to 20% of the
neurons express this enzyme (Bernstein et al., 2005). The importance of BH4 in the
metabolism of NO is reflected by the corresponding distribution of the activity of both BH4
and NO in the brain (Thöny et al., 2000). Functionally, NO may act as a hormone,
neurotransmitter, paracrine messenger, mediator, cytoprotective and cytotoxic molecule
(Bernstein et al., 2005).
In most brain structures NO modulates the release of the neurotransmitters acetylcholine,
catecholamines, serotonin and GABA, and the amino acids glycine, glutamate and
aspartate (Prast and Philippu, 2001). The effect of NO on the release of monoamines within
a particular brain area seems to be modulated by glutamate. Glutamate binds to the N-
methyl-D-Aspartate (NMDA) receptor, which results in Ca2+ influx, stimulation of nNOS
and increased production of NO. NO in turn influences glutamatergic neurotransmission
by directly inhibiting the NMDA receptor function (Prast and Philippu, 2001; Akyol et al.,
2004; Bernstein et al., 2005). 
NO may act as a free radical due to its unpaired electron and can be toxic at higher concen-
trations (Akyol et al., 2004; Bernstein et al., 2005). Under certain conditions, e.g. when
the availability of arginine or BH4 is limited, NOS enzymes produce oxygen-derived
radicals such as peroxynitrite (Koshimura et al., 2000; Akyol et al., 2004). It has been
suggested that BH4 itself may act as a protecting factor for NO toxicity and that this
compound may also protect dopaminergic neurons from oxidative stress (Koshimura et
al., 2000; Nakamura et al., 2001).
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In animal experiments it was found that glucocorticoids inhibit induction of NO formation by
a direct influence on the enzyme NO synthase as well as by reducing the availability of BH4
(Hattori et al., 1997). An overactivated HPA-axis, like in depression, could therefore decrease
the BH4 concentration and consequently may affect both monoamine and NO metabolism.
The suprachiasmatic nucleus (SCN) is a small hypothalamic structure, considered to be a
major circadian and circannual pacemaker of the mammalian brain. Disturbances in the
biological clock function are characteristic for many disorders including depression. Since
the NO/cGMP pathway is prominently involved in the mammalian circadian clock, it is
conceivable that NOS expression may be disturbed in depression with or without atypical
symptoms. In this respect the number of NOS immunoreactive neurons in depression has
been demonstrated to alter with the seasons (Bernstein et al., 1998; Bernstein et al., 2005;
Swaab et al., 2005). 
7. NO and affective disorders
As can be inferred from table 2, in depressed patients mostly a decrease of NO was found
in plasma or serum. The data, however, are far from unequivocal. The sparse findings on
NO in bipolar disorder, all published by the same Turkish group of investigators, suggest
higher levels of metabolites of NO (Savas et al., 2002; Savas et al., 2006). Since it is
impossible to measure the gaseous compound NO directly, most investigators use the
measurement of its metabolites nitrate and nitrite. However, the determination of
nitrate/nitrite may be influenced by diet, environmental factors and even the glassware
used. A more reliable parameter used as an indication of NO synthesis may be the ratio
between the amino acids citrulline and arginine, which can easily be determined in the
plasma or serum (Finkel et al., 1996; Fekkes et al., 2007).
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DPHR
NOsynthase
arginine g citrulline + NO
tetrahydrobiopterin q-dihydrobiopterin
Figure 2. 
Synthesis of nitric oxide (NO)
Central question of the thesis
Since the late eighties of the past century there is a growing interest in the role of NO in the
pathophysiology of a variety of neuropsychiatric disorders, particularly schizophrenia and
affective disorders. The functional activity of this gas is closely linked to the synthesis and
degradation of pterins. Therefore studies were conducted to evaluate the potential role of
both pterins and parameters of NO activity in various types of affective disorders.
The first chapter of this thesis describes the differences between three major groups of
affective disorders: major depression, seasonal affective disorder and bipolar-I disorder. In
the symptomatic as well as in the recovered state several biochemical parameters related to
the pterins and NO metabolism were measured.
The second chapter focuses on a group of patients with a severe, medication-resistant,
depressive disorder. The effect of electroconvulsive therapy on various biochemical
parameters was studied. 
In the third chapter patients with seasonal affective disorder are described. These patients
showed atypical depressive symptoms. Biochemical measures before and after light
therapy are presented.
The fourth chapter describes NMDA receptor related amino acids in bipolar manic and
bipolar euthymic patients.
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Abstract
Background: There is an increasing interest in the role of nitric oxide (NO) and pterines in
the pathophysiology of neuropsychiatric disorders. The results so far show an inconsistent
pattern. 
Methods: In the present study neopterin and a measure of NO synthesis in plasma of
symptomatic and euthymic bipolar affective patients were compared to those of patients
with a major depression and healthy controls. As an index of NO synthesis, the ratio of the
amino acids citrulline and arginine (Cit-Arg ratio) was calculated. Neopterin is a bypass
product in the synthesis of tetrahydrobiopterin, which is a cofactor of NO synthase.
Results: The results indicate that both neopterin and the Cit-Arg ratio are decreased in
bipolar affective patients, irrespective their symptomatic status. In addition, an association
between the values of the Cit-Arg ratio and the neopterin level was observed, which is
suggestive for a low BH4 activity.
Conclusion: Nitric oxide formation may be endangered in bipolar affective disorder.
Reprinted from Neuropsychobiology 2006;54:75-81, Copyright (2006), 
with permission from Elsevier.
 
Introduction
Since two decades there has been an increasing interest in the role of nitric oxide (NO) in
the pathophysiology of a variety of neuropsychiatric disorders. In the brain many
processes are linked to NO, in that it influences the storage and uptake and/or release of
most other neurotransmitters as well as certain neuropeptides and it exerts a strong
influence on glutamatergic neurotransmission [1,2]. 
With respect to the neuropsychiatric disorders, indices of NO functionality have been
investigated in schizophrenia, autism, obsessive-compulsive disorder, Alzheimer's
disease and affective disorders, yielding contradictory results suggestive for an
enhanced or a decreased synthesis of NO [3,4]. Much work has been done to elucidate
the contribution of NO to the pathophysiology of mood disorders. As described by
Bernstein and coworkers, a reduced synthesis of NO may be associated with major
depression [5]. The results suggest a dichotomy between unipolar and bipolar affective
disorder, in that in the blood of the latter increased concentrations of NO have been
found [6,7]. Furthermore, NO synthase is highly expressed in hypothalamic neurons [8],
the brain region that is implicated in the pathogenesis of stress-related disorders such as
depression [9]. Concerning the latter, pteridines are also involved and a limited number
of studies suggest an increased plasma concentration of neopterin in major depression
[10,11].
Since both neopterin and NO have been implicated in depressive disorders, a study was
conducted in patients with major depression or bipolar affective disorder. The NO
synthesis was approximated by calculation of the ratio between the plasma levels of the
amino acids citrulline and arginine (Cit-Arg ratio). Both NO and citrulline are formed
from arginine, a reaction catalyzed by the enzyme NO synthase, and the Cit-Arg ratio is
regarded as an index of the NO synthesis [12,13]. 
In a previous study conducted in patients suffering from a severe major depression, the
ratio between the plasma levels of phenylalanine and tyrosine (Phe-Tyr ratio) appeared to
be increased as compared to normal controls [14]. The Phe-Tyr ratio provides a reliable
measure of the phenylalanine hydroxylase activity and may also be regarded as an
indirect measure of tetrahydrobiopterin (BH4) activity [15]. Since neopterin and BH4
share the same precursor and plasma levels of BH4 were found to be decreased in
depressed patients and increased in bipolar manic patients [16], the Phe-Tyr ratio was
measured in the present study as well.
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Materials and methods
Experimental procedures
The protocols were approved by official recognized medical ethics committees. The
projects were performed in accordance with the Helsinki Declaration. Written informed
consent was obtained from all patients.
Subjects
The first group comprised 20 patients, suffering from a Major Depressive Disorder with
Melancholic Features (MDMF; n=20). The second group consisted of patients with a Major
Depressive Disorder with Seasonal Pattern (MDSP; n=19). Patients from groups 1 and 2
were referred to the Department of Psychiatry of the Erasmus University Medical Centre for
electroconvulsive treatment (ECT) and light therapy respectively. All patients were at least 1
week free of medication. The third group consisted of patients with a relapse of a Bipolar-I
Disorder (BP-I) with either a Manic Episode (n=20) or a Depressed Episode (n=12) who were
enrolled from the outpatient department of Delta Psychiatric Centre. The BP-I manic
patients were treated with lithium (n=14) and/or mood stabilizing anticonvulsants (n=14).
Twelve patients were treated with antipsychotics in addition to the mood stabilizer,
whereas antidepressants were not prescribed. The BP-I depressed patients were treated
with lithium (n=7) and/or moodstabilizing anticonvulsants (n=5). Six patients were treated
with additional antidepressants and 4 patients with antipsychotics. Excluded were patients
with clinically relevant somatic disorders or comorbid DSM axis-I disorders. 
The first control group consisted of euthymic bipolar patients with lithium prophylaxis as
monotherapy (BP-EU; n=12), who were free of symptoms for at least 6 months. The second
control group comprised healthy persons (n=20), who were extracted from a large
database. Demographic data and baseline scores of the 3 patient groups and the charac-
teristics of the 2 control groups are presented in table 1.
Assessment
Diagnoses in the group of patients with MDMF were made on the basis of a semi-
structured interview including the Schedule for Affective Disorders and Schizophrenia
(SADS) [17]. The severity of depression in the groups with MDMF and BP-I depressed
episode was assessed with the Hamilton Rating Scale for Depression (HAMD) [18]. Manic
symptoms were rated with the Young Mania Rating Scale (YMRS) [19]. Depressive
symptoms in the MDSP patients were established according to the Beck Depression
Inventory (BDI) including the addendum for atypical symptoms (BDI-add) [20]. All patients
met the criteria for the different DSM-diagnoses. In bipolar patients data from
retrospective life charts [21] were included in the diagnostic procedure. 
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Patients with MDMF underwent ECT (mean: 11 times; twice weekly) since they were all
non-responders to a complete pharmacological treatment algorithm including lithium
addition and MAO-inhibitors. MDSP patients received a standard regimen of light therapy
on 5 consecutive mornings. Patients with a relapse of BP-I were treated, depending on the
phase, with either addition of an antidepressant or a high potency benzodiazepine and/or
an antipsychotic to the used mood stabilizing agents. In all groups the first assessment of
symptomatology was performed directly before treatment (baseline scores). The second
assessment of the patients with MDMF and MDSP was done after treatment with ECT or
light therapy respectively, and for the BP-I patients this was done after recovery of clinical
symptoms. The latter was defined as an outcome score of less than 10 on the HAMD or less
than 6 on the YMRS or a more than 50% decrease from the baseline.
Blood drawing and biochemical assays
A venous blood sample was drawn before 10.00 a.m. and plasma was prepared by differ-
ential centrifugation (20 min at 2650 g and 20ºC) within 2 hours. Blood of the patients was
obtained before and after treatment. Plasma samples were stored at -80ºC until assay.
Amino acids and neopterin were assayed by high performance liquid chromatography
with fluorometric detection according to the methods described previously [14,22]. The
Cit-Arg and the Phe-Tyr ratios were calculated by dividing the plasma level of citrulline by
that of arginine and the plasma level of phenylalanine by that of tyrosine respectively.
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Group Number (mean age and %males) Depression Scores Manic scores
MDMF 20 (52 yrs; 35%) 31.4 ± 7.7 --
MDSP 19 (41 yrs; 5%) 22.9 ± 12.1 --
BP-I manic 20 (50 yrs; 70%) -- 21.7 ± 6.1
BP-I depressed 12 (47 yrs; 58%) 20.6 ± 6.7 --
Healthy controls 20 (51 yrs; 40%) -- --
BP-EU 12 (40 yrs; 67%) -- --
Data are presented as mean ± SD.
MDMF=Major Depressive disorder with Melancholic Features
MDSP=Major Depressive disorder with Seasonal Pattern
BP-I=Bipolar-I  disorder, Manic or Depressed
BP-EU=Bipolar-I disorder, euthymic controls
Depression scores: Hamilton Rating Scale for Depression in MDMF and BP-I depressed groups; Beck
Depression Inventory with addendum for atypical features in MDSP group.
Manic Scores: Young Mania Rating Scale
Table 1. 
Demographic data and baseline scores of the different groups.
 
Statistics
Data are presented as mean ± SD. BP-I depressed and manic were combined in the group
BP-I symptomatic (n=32). Data were analyzed by one-way analysis of variance (ANOVA)
and post-hoc comparisons were done by Bonferroni's multiple comparison test. Neopterin
levels were correlated with the Cit-Arg ratio and Phe-Tyr ratio using the Pearson correlation
test. Results were considered significant when p < .05. 
Results
The baseline scores for the MDMF, MDSP, BP-I depressed and BP-I manic groups are shown
in table 1. After treatment the scores on the depression and mania ratings in the different
patient groups were significantly reduced (MDMF: 11.0 ± 10.1, p<0.0001; MDSP: 9.7 ±
8.0, p<0.0001; BP-I: depressed: 3.4 ± 3.3, p<0.0001 and BP-I manic: 1.6 ± 2.0, p<0.0001).
The percentage symptomatic improvement was for the MDMF, MDSP, BP-I depressed and
BP-I manic 65, 58, 83 and 93% respectively. 
Values for the Phe-Tyr and Cit-Arg ratios and for neopterin are depicted in tables 2
(baseline) and 3 (after treatment). Good responders on ECT (n=15) or on light therapy
(n=13) showed biochemical values that were not different from those of the less
responding patients. When comparing the BP-I depressed with the BP-I manic patients no
significant differences were found in the values for the Phe-Tyr ratio (0.95 ± 0.20 vs. 0.89 ±
0.21), the Cit-Arg ratio (0.44 ± 0.29 vs. 0.48 ± 0.23) and for neopterin (12.05 ± 4.94 vs.
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Phe-Tyr Cit-Arg Neopterin (nmol/l)
MDMF (n=20) 1.03 (0.14) 0.48 (0.14) 21.67 (8.18)
MDSP (n=19) 0.94 (0.21) 0.56 (0.19) 22.54 (7.62)
BP-I (n=32) 0.91 (0.21) 0.46 (0.25) 14.51 (9.98) *
Healthy controls (n=20) 0.94 (0.13) 0.51 (0.12) 18.84 (4.01)
BP-EU (n=12) 0.99 (0.13) 0.40 (0.16) 14.76 (6.0)
* MDMF vs. BP-I: p=0.02; MDSP vs. BP-I: p=0.007
Data are presented as mean (SD)
MDMF=Major Depressive disorder with Melancholic Features
MDSP=Major Depressive disorder with Seasonal Pattern
BP-I=Bipolar-I  disorder, Manic and Depressed
BP-EU=Bipolar-I disorder, euthymic controls
Table 2. 
Biochemical parameters in the various groups at baseline.
 
15.99 ± 11.92 nmol/l). Therefore, the BP-I depressed and BP-I manic patients were
combined in one symptomatic, BP-I group (n=32). 
As can be inferred from table 2, the baseline value for neopterin in the symptomatic BP-I
group is significantly lower as compared to both the MDMF and MDSP group. In addition,
this value was decreased in the BP-EU controls. Furthermore, the Phe-Tyr ratio in the MDMF
group is higher than in the groups with MDSP, symptomatic BP-I and healthy controls,
albeit not significant. Although not reaching the level of significance, the Cit-Arg ratio is
lower in the bipolar groups.
The biochemical parameters measured after treatment, are given in table 3. It can be seen
that the differences in neopterin levels persisted after treatment, while the Phe-Tyr ratio in
the MDMF group normalized (paired t-test; p<0.0001). In contrast to baseline, the Cit-Arg
ratio in the MDMF group increased after treatment (paired t-test; p= 0.015), whereas this
ratio did not change in the MDSP and symptomatic BP-I group.
Since psychotropics and mood stabilizers like e.g. antidepressants and valproic acid have
been demonstrated to affect levels of amino acids [23,24], a group of 12 patients using
only lithium (MBP-I) was composed from the symptomatic BP-I group. Interim analysis
showed no effect of the plasma level of lithium on the biochemical parameters.
Figure 1 shows the Cit-Arg ratios before and after treatment in the symptomatic BP-I
patients on lithium monotherapy (MBP-I) as well as in the MDMF and MDSP groups. In
addition, these ratios are given for the BP-EU group and the healthy control group. Before
treatment the Cit-Arg ratio in the MBP-I group (n=12) was significantly lower than in the
MDSP group (p=0.002) and the healthy controls (p=0.024). After treatment these
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Phe-Tyr Cit-Arg Neopterin (nmol/l)
MDMF (n=20) 0.89 (0.13) 0.59 (0.25) 23.62 (8.24)
MDSP (n=19) 0.95 (0.18) 0.52 (0.16) 21.95 (5.63)
BP-I (n=32) 0.91 (0.14) 0.45 (0.22) 14.57 (6.76) *
Healthy controls (n=20) 0.94 (0.13) 0.51 (0.12) 18.84 (4.01)
BP-EU (n=12) 0.99 (0.13) 0.40 (0.16) 14.76 (6.00) #
* MDMF vs. BP-I: p<0.0001; MDSP vs. BP-I: p=0.001
# MDMF vs. BP-EU: p=0.004; MDSP vs. BP-EU: p=0.037
Data are presented as mean (SD)
MDMF=Major Depressive disorder with Melancholic Features
MDSP=Major Depressive disorder with Seasonal Pattern
BP-I=Bipolar-I  disorder, symptomatic
BP-EU=Bipolar-I disorder, euthymic controls
Table 3. 
Biochemical parameters in the various groups after treatment.
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Fig. 1. Cit-Arg ratios (± SD) in plasma of patients suffering from a Major Depressive Disorder with Melancholic Features
(MDMF; n=20) or from a Major Depressive Disorder with Seasonal Pattern (MDSP; n=19) and in patients with a Bipolar-I
Disorder with either a Manic Episode or a Depressed Episode on lithium monotherapy (MBP-I; n=12) before and after
appropriate treatment. In addition, these ratios are given for the euthymic bipolar patients with lithium prophylaxis as
monotherapy (BP-EU; n=12) and for the healthy control group (HC; n=20). *, p=0.002 and p=0.024 versus MDSP before
treatment and HC, respectively. +, p=0.006 and p=0.007 versus MDSP after treatment and HC, respectively. #, p=0.004
and p=0.039 versus MBP-I after treatment and BP-EU, respectively. 
Fig. 2. Neopterin concentrations (± SD) in plasma of patients suffering from a Major Depressive Disorder with
Melancholic Features (MDMF; n=20) or from a Major Depressive Disorder with Seasonal Pattern (MDSP; n=19) and in
patients with a Bipolar-I Disorder with either a Manic Episode or a Depressed Episode on lithium monotherapy (MBP-I;
n=12) before and after appropriate treatment. In addition, these ratios are given for the euthymic bipolar patients with
lithium prophylaxis as monotherapy (BP-EU; n=12) and for the healthy control group (HC; n=20). *, p=0.021 and p=0.009
versus MDMF and MDSP before treatment, respectively. +, p<0.0001 and p=0.002 versus MDMF and MDSP after treat-
ment, respectively. #, p=0.003 and p=0.033 versus MDMF and MDSP after treatment, respectively. 
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differences persisted (p=0.006 and p=0.007, respectively). The Cit-Arg ratio was also
significantly lower in both the MBP-I and BP-EU control group (n=12) as compared to the
MDMF group (p=0.004 and p=0.039, respectively).
The results for the plasma neopterin levels are depicted in figure 2. Before treatment,
neopterin was significantly lower in the MBP-I group (n=12) than in the MDMF (p=0.021)
and MDSP group (p=0.009). After treatment these differences persisted (p<0.0001 and
p=0.002, respectively). Neopterin levels were also significantly lower in the BP-EU group
(n=12) than in the MDMF (p=0.003) and MDSP group (p=0.033). The neopterin levels as
well as the Cit-Arg ratio in the MBP-I group (n=12) after treatment were not different from
those in the BP-EU control group (n=12).
In the symptomatic BP-I group (n=32) the values of neopterin were positively correlated with
the Cit-Arg ratio (r=0.44, p=0.012). A comparable positive correlation (r=0.31, p=0.044)
was found after treatment in the total group of bipolar patients (n=44, including the 12
euthymic controls). No correlation was found between the Phe-Tyr ratio and neopterin
levels.
Discussion
The present study demonstrates that patients with bipolar-I disorder show, irrespective of
the presence of depressive or manic symptoms, a significantly lower plasma level of
neopterin as compared to patients suffering from a major depressive disorder with
melancholic features or from a major depressive disorder with seasonal pattern. In fact,
neopterin is 33-35% lower in the bipolar patient groups with or without symptoms as
compared to the groups with depressed patients, suggestive for a decreased activity of BH4.
Since most of the patients from the bipolar groups were treated with psychotropics and
mood stabilizers other than lithium, and these compounds are known to modify the here
studied biochemical parameters [23-27], symptomatic bipolar patients on monotherapy
with lithium were compared to the euthymic monolithium bipolar patient control group.
Analyses of the biochemical parameters in the monolithium symptomatic subgroup
revealed similar results with respect to decreased neopterin levels. 
In addition, the symptomatic and euthymic subgroup of bipolar-I patients on lithium
monotherapy both demonstrated a lower Cit-Arg ratio as compared to healthy controls as
well as to the two patient groups with depressive disorders. This ratio is regarded as an
index of the NO synthesis [13] and/or NO synthase activity [12] and thus, NO formation may
be endangered in bipolar patients.
Given the absence of an effect of lithium on the plasma concentration of the biochemical
parameters and the data from the literature demonstrating an enhancing effect of lithium
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on NO synthesis [28,29], the results from the present study are unlikely to be influenced by
lithium maintenance therapy.
The lower neopterin concentration in bipolar patients may be caused by a decreased
activity of the enzyme GTP cyclohydrolase, resulting in a lower conversion of guanosine
triphosphate to 7,8-dihydroneopterintriphosphate. The latter is not only the precursor of
neopterin, but also of BH4, which is the essential cofactor in the production of citrulline
and NO from arginine [30,31]. Therefore, the lower Cit-Arg ratio suggests not only a
decreased formation of NO, but may also indicate a lower activity of BH4. The latter
substance is also an essential cofactor for the enzymatic hydroxylation of phenylalanine,
tyrosine and tryptophan, from which the major monoamine neurotransmitters are
synthesized. However, a decreased activity of the enzyme NO synthase is also a possibility.
Thus, both the lower values of neopterin and the Cit-Arg ratio and the observed
association between these parameters found in bipolar affective disorders, indicates a
reduced activity of BH4 and a decreased formation of NO in this group, in contrast to the
group of major depressive disorders with melancholic features or a seasonal pattern. These
findings are in agreement with those reported recently by Richardson et al.[32] in a large
sample of patients with schizophrenia and support the idea that bipolar affective disorder
and schizophrenia share common pathophysiological patterns [33]. 
With respect to NO, numerous studies have substantiated the view that this molecule has
multiple cellular and molecular targets and that it may functionally act as a hormone,
neurotransmitter, mediator and cytotoxic or cytoprotective molecule [1]. In addition, NO
participates in the control of various neurosecretory processes, especially of the
corticotropin releasing hormone system [34]. Given its participation in many physiological
and chemical reactions in the brain, NO has been investigated in a variety of neuropsy-
chiatric disorders [2]. In schizophrenia, data do not show a clear picture as to whether there
is more or less NO synthesis. In a recent review, Bernstein and co-workers conclude that it is
unlikely that alterations in NO metabolism are unique to or indicative of schizophrenia [1]. 
The role of NO in the pathophysiology of affective disorders has also been studied. In
patients with major depression, a reduced NO synthase activity has been found in various
brain regions [5,8,35-37]. Measurement of the NO metabolites nitrite and nitrate in blood
of depressed patients revealed either decreased [38,39] or elevated levels [40]. In bipolar-I
patients, plasma levels of NO were found to be higher [6,7]. Four studies with the SSRI
paroxetine presented with conflicting results, in that Finkel et al. [12] and Goodnick and
Goldstein [41] reported decreased serum nitrite and nitrate levels following paroxetine
treatment, whereas Lara et al. [42] and Chrapko et al. [27] found the reverse.
From the current study it can be concluded that the NO synthesis is state independently
impaired in patients with bipolar affective disorders. The results, however, have to be
interpreted with some caution. First, no direct measurement of actual NO synthesis is
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presented. As an index of NO synthase activity the plasma concentrations of arginine and
citrulline were measured and the ratio of these amino acids was calculated. Although the
amino acid citrulline is regarded a more stable marker of NO synthesis than measurement
of the blood levels of nitrate/nitrite [43], it has to be mentioned that citrulline originates not
only from NO production but also from the action of the enzyme ornithine carbamoyltrans-
ferase. Furthermore, the enzyme argininesuccinate synthase is capable of citrulline
catabolism in mammals. Second, the question remains whether peripheral measurements
of NO synthesis reflect NO activity in the central nervous system or not, although some
investigators think it does [4,44]. Finally, the contradictory results from the literature may
be an expression of the fundamental concern in neuropsychiatry, in that descriptive
psychiatric diagnoses are by no means uniform neither biologically nor clinically. 
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Effect of electroconvulsive therapy on
biopterin and large neutral amino acids in
severe, medication-resistant depression.
Rocco Hoekstra, Walter W. van den Broek, Durk Fekkes, Jan A. Bruijn, Paul G. H. Mulder,
Lolke Pepplinkhuizen. 
Abstract
Biopterin, neopterin and the large neutral amino acids (LNAA) i.e. phenylalanine, tyrosine,
tryptophan, isoleucine, leucine and valine were measured in plasma of 20 severely
depressed inpatients before and after a course of electroconvulsive therapy (ECT). 
These patients showed a significantly lower plasma biopterin concentration at baseline in
comparison with healthy controls. After treatment an increase in biopterin was found,
which was statistically significant in the depressed patients with psychotic features. The
plasma phenylalanine-tyrosine-ratio, which previously increased, normalised after ECT.
Mean tryptophan concentration was lower in depressed patients than in normal controls.
The patients who responded to ECT showed an increase in the tryptophan concentration
and its ratio (tryptophan/LNAA) after treatment. 
Our results suggest that ECT increases biopterin, which probably results in synthesis of
amino acids, especially tyrosine. Furthermore, ECT seems to increase cerebral tryptophan
availability because of less tryptophan catabolism parallel with biopterin activation. More
research is required to see if biopterin could be useful as a biological marker for the
depressive state in this subgroup of patients, because this compound seems to play an
important role in the etiology and treatment of depression.
Reprinted from Psychiatry Research 2001;103:115-123, Copyright (2001), 
with permission from Elsevier.
 
Introduction
The metabolism of biogenic amines has been hypothesised to play a key role in the
pathophysiology of affective disorders. A functional deficiency of cerebral epinephrine and
serotonin is still the most widely accepted model for understanding the biology of
depression and the therapeutic action of antidepressant treatments (van Praag, 1982).
Tetrahydrobiopterin (BH4) is the essential cofactor for the hydroxylation of phenylalanine,
tyrosine and tryptophan, which is the rate limiting step in the formation of dopamine,
norepinephrine and serotonin, respectively (Kapatos et al., 1993; Levine, 1988).
Independent from its function as cofactor for the hydroxylation, BH4 also enhances the
release of these neurotransmitters from nerve terminals (Mataga et al., 1991; Wolf et al.,
1991). A link between BH4 and both nitric oxide, a neuroendocrine modulator of the HPA-
axis, and the immune system has been hypothesised (van Amsterdam and Opperhuizen,
1999). 
BH4 is synthesised de novo from guanosine triphosphate (GTP) which is converted to
dihydroneopterin triphosphate (NHPT3). The latter is converted by a series of tetrahydro
intermediates to BH4. The concentration of cellular BH4 is dependent on this pathway and
a salvage mechanism that converts quinonoid dihydrobiopterin to BH4 by the enzyme
dihydropteridine reductase. Hydrolysis of NHPT3 yields dihydroneopterin, which is
excreted in urine with its oxidative product neopterin, as are BH4 and its oxidative products,
dihydrobiopterin and biopterin (Levine, 1988) (figure 1). 
Increased neopterin secretion is a sensitive marker of activation of cell-mediated immunity.
Interferon-gamma, which is produced and secreted by activated T cells, is probably the most
important activator of pteridine synthesis and release by activated cells of the monocyte /
macrophage lineage (Hüber et al., 1984; Maes et al., 1994). Immune-activation not only
increases synthesis of pteridines but also tryptophan catabolism through induction of
indoleamine 2,3-dioxygenase (IDO) and will therefore influence serotonin metabolism
(Maes et al., 1993). There is evidence for immune activation in depression (Maes et al.,
1993). Indeed, plasma levels of tryptophan and the ratio of tryptophan to the sum of amino
acids, which compete for the same cerebral uptake mechanism, i.e. phenylalanine, tyrosine,
isoleucine, leucine and valine, have been found to be lower in depressed subjects than in
normal control subjects (DeMyer et al., 1981; Møller, 1985).
Many studies have focused on the catecholamine hypothesis of depression (Schildkraut,
1965). Recent challenge studies have renewed interest in this theory (Berman et al., 1999).
Levels of phenylalanine and tyrosine have been studied in depressed patients. A lower
tyrosine level or a lower tyrosine ratio to competing amino acids is often reported.
Antidepressant medication seems to have no effect on these measures (e.g. Møller et al.,
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1981). Anderson reported a reduction of the ratio of phenylalanine to tyrosine after
response to ECT, suggestive of increased hydroxylation by BH4 after treatment (Anderson
et al., 1994).
Because of its role in dopamine, norepinephrine and serotonin metabolism, BH4 has been
studied in depressed patients. Contradictory results have been reported (Abou-Saleh et al.,
1995; Anderson et al., 1992; Blair et al., 1984; Bonaccorso et al., 1998; Coppen et al.,
1989; Duch et al., 1984; Garbutt et al., 1985). In these studies, however, urinary biopterin
was measured. As can be expected from the metabolism and excretion of BH4, plasma
measurements are not comparable with these results. 
Hashimoto and Knapp found an increased plasma biopterin in depressed patients
(Hashimoto et al., 1990; Knapp and Irwin, 1989). Methodological factors make these and
several other studies difficult to compare. The population was often not well defined or not
very restricted. 'Major depression' could represent too broad a spectrum of pathology for
studying a biological marker. Besides, in these studies patients were using several
psychotropic drugs.
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Figure 1. 
Biosynthesis of tetrahydrobiopterin and its effect on the hydroxylation of phenylalanine, 
tyrosine and tryptophan.
The same problems arise when studying neopterin, as mentioned above a known marker
of immunity. An increase in the concentration of neopterin could be expected in plasma of
depressed patients. However, recently O'Toole found no significant difference in plasma
neopterin between patients and normal controls, while Maes and Dunbar found increased
levels in urine (Dunbar et al., 1992; Maes et al., 1994; O'Toole et al., 1998). 
Studying strictly selected, severely depressed, medication free inpatients, we tried to answer
the following questions: (1) Is the plasma concentration of biopterin lowered in this
population, compared to normal controls, and is the neopterin concentration increased? (2)
Are certain clinical features like psychotic symptoms or the response to treatment related to
even lower concentrations of biopterin? (3) Is there an increase in plasma biopterin after
effective treatment (ECT) with a reverse tendency for plasma neopterin? (4) Are the concen-
trations of the amino acids, on which tetrahydrobiopterin acts as a cofactor, changed before
and after treatment? More specifically, is the phenylalanine-tyrosine-ratio, a known
measure for hydroxylation activity of BH4, higher in the depressed population in comparison
with normal controls and is this ratio lowered after successful treatment? And is tryptophan
or the tryptophan-ratio decreased before treatment and increased after that?
Methods
The protocol of this study was approved by the Ethics Committee of the University Hospital
Rotterdam. Informed consent was obtained from 20 patients, 7 male and 13 female, with
a mean age of 52 (SD 13.1). Patients who were pregnant or suffered from serious diseases
known to influence the biopterin metabolism, like infectious diseases, autoimmune
disorders, neoplastic disorders, Parkinson disease or dementia, were excluded from this
study. They had a DSM-IV diagnosis of major depression, which was assigned by two
psychiatrists performing the depression part of the Schedule for Affective Disorders and
Schizophrenia (SADS) (Spitzer and Endicott, 1977). Psychotic and melancholic features
were assessed during this interview. The diagnosis of psychotic depression was only made
when the patient was having definite mood-congruent delusions according to the SADS.
The severity of the depression was scored using the Hamilton Rating Scale for Depression
(HRS-D) (Hamilton, 1969). Improvement was measured with the HRS-D before and after
the course of ECT and was defined as an outcome score of less than 10 or a more than 50%
decrease from the baseline. 
Furthermore, recommendation for inpatient ECT had been made by the treating psychia-
trists and an independent psychiatrist. In The Netherlands this recommendation is almost
exclusively made when a patient with a severe major depression has failed to respond to
prior treatment with a tricyclic antidepressant, lithium addition or an irreversible
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monoamine oxidase inhibitor. Twenty-nine healthy volunteers, 16 male and 13 female,
with a mean age of 37 (SD 8.3), served as controls. 
ECT was administered twice weekly. All patients were free of antidepressants for at least 7
days before the ECT course. In cases of severe agitation, only a short-acting benzodi-
azepine or droperidol was given on the morning of treatment. ECT was started with
unilateral brief-pulse, constant current stimulation, using the Thymatron DGx. The initial
dosage of the stimulus was based on the age of the patient. After intravenous adminis-
tration of methylatropine, alfentanil and metoclopramide, anaesthesia was achieved with
intravenous etomidate and succinylcholine in this order during all sessions. If there was no,
or hardly any, clinical improvement after four sessions, as measured by the HRS-D,
unilateral ECT was switched to bifrontotemporal ECT. In four patients ECT was started
bilaterally because of the severity of the depression and/or the earlier good response to this
mode of treatment. The decision to stop was made when no clinical improvement was
observed by the treating psychiatrist after four to six bilateral treatments or when complete
remission was obtained. Thus, this resulted in a different number of treatments.  
A fasting, venous blood sample was taken in the morning before the first ECT adminis-
tration. The morning after the last ECT administration the second sample was collected.
The HRS-D score was also determined. 
Immediately after venapuncture, plasma was prepared by a 20-min centrifugation step at
2650 g and stored at -80 0C. Neopterin and biopterin were measured after acid oxidation
of the reduced forms of both pteridines as described earlier (Fukushima and Nixon, 1980).
Plasma (0.4 ml) was oxidised in 0.1 ml 1 M trichloroacetic acid and 0.05 ml iodine solution
(0.5% I2, 1%KI in 0.2 M trichloroacetic acid). For each assay, different amounts of
neopterin and biopterin were added to a plasma pool for the determination of the percent
recovery. After standing for 60 min under reduced light, excess iodine was reduced by the
addition of 20 µl of 1% ascorbic acid solution and the mixture was centrifuged at 12 000 g
for 15 min at 4 ºC. The supernatant (0.4 ml) was transferred to an amber glass vial, and 10
µl was injected directly onto the analytical column using an HPLC system with an
autosampler and a fluorescence detector (Hewlett Packard, Series 1100). We used a
Hypersil C18 column (2.1 x 200 mm, 5 µm), which was protected by a narrow bore guard
column (2.1 x 20 mm) of the same material (Hewlett Packard). The separation was achieved
using an aqueous 15 mmol/l potassium phosphate buffer, pH 6.45 and a stepwise eluant
gradient with methanol (from 1.5-2 min to 10%, from 4 to 5 min to 100%, and from 6 to
8.3 min to 0%). Total run time was 14 min, the flow rate was set at 0.4 ml/min, the column
temperature was 50 ºC and the excitation and emission wavelengths were 360 and 440
nm, respectively. Compounds were quantitated by their peak height in comparison with
external standards. Neopterin and biopterin were eluted at approximately 2.2 and 4.8 min,
and the detection limits of both compounds (at a signal-to-noise ratio of 3) were 2 and 3
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fmol (0.2 and 0.3 nmol/l), respectively. Recoveries of neopterin and biopterin added to
plasma samples were 100-140 and 95-110%, respectively. The intra-assay coefficients of
variation for neopterin and biopterin were less than or equal to 2.4 and 2.1%, respectively.
The interassay coefficients of variation for these compounds, determined on six different
days, were 3.8 and 2.8%, respectively. 
The amino acids phenylalanine, tyrosine, tryptophan, isoleucine, leucine and valine were
measured by means of high performance liquid chromatography (Fekkes et al., 1995). The
tryptophan ratio was calculated as 100 times the concentration of tryptophan divided by
the summed concentration of the other large neutral amino acids, i.e. phenylalanine,
tyrosine, isoleucine, leucine and valine (Fernstrom and Wurtman, 1972).
For statistical analysis a two-tailed  Student t test was used. Data were expressed as mean
and standard deviation. Statistical significance was defined as p<0.05.
Results
The mean score of the 20 patients on the HRS-D was 31, before the start of the ECT
procedure, after unsuccessful medication treatment. After ECT, the mean HRS-D score was
11. According to the above-mentioned definition, 15 patients had a good clinical
response. All patients showed melancholic features, and 10 patients showed mood-
congruent psychotic features. Four patients got only unilateral and four patients received
exclusively bilateral ECT. The total group received a mean of 11 ECT administrations. One
patient used 2 mg of lorazepam and 10 mg of droperidol during the course of ECT,
although the post-treatment blood sampling took place 5 days later while the patient was
free of medication. Five patients had already restarted an antidepressant treatment, like
imipramine, lithium or tranylcypromine, for 1-4 days before the post-treatment blood
sample was taken. These five patients were free of medication before and during the ECT
course. 
Mean biopterin level in the depressed patients was 5.7 nmol/l while that in the normal
controls was 7.0 nmol/l (p=0.002). After ECT, the mean biopterin concentration normalised
to 6.3 nmol/l, but the difference between pre- and post-treatment was not significant (Table
1). 
When only the subcategory of psychotic patients was studied, a significantly lower pre-
treatment level was found compared to the normal controls, i.e. 5.5 nmol/l vs. 7.0 nmol/l
(p=0.04). Psychotic depressed patients had a significantly increased level of biopterin after
treatment, i.e. 6.5 nmol/l (p=0.03). Non-psychotic patients did not show any increase in
the biopterin level (Table 2). 
Lower pre-treatment levels were also found in patients who responded to ECT, i.e. 5.6
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nmol/l (p=0.003). The responders showed an increase in biopterin from 5.6 nmol/l to 6.4
nmol/l, whereas this concentration did not change in the non-responders (Table 3). 
Neopterin concentration was not significantly higher in the total group of depressed
patients when compared to normals, viz. 21.7 nmol/l vs. 19.6 nmol/l. After treatment the
neopterin level increased significantly to 23.62 nmol/l (p=0.03). 
The neopterin-biopterin ratio was significantly increased before treatment compared to
the controls. (4.0 (2.0) vs. 2.9 (1.1); p=0.01) However, ECT did not change this ratio.
The depressed patients had a mean phenylalanine level of 52.8 (8.9) µmol/l and, after
treatment, the level slightly decreased to 49.4 (6.8) µmol/l. The mean level in healthy
controls is 56.0 (6.9) µmol/l. Tyrosine concentrations increased from 52.7 (11.9) to 56.3
(13.5) µmol/l. The mean level in healthy controls is 62.0 (14.4) µmol/l. Although these pre-
and post-values were not significantly different, the phenylalanine-tyrosine (P-T) ratio did
show a significant decline after treatment from 1.0 to 0.9 (p<0.0005). The subgroups with
psychotic features and the responders had comparable results with only the phenylalanine
-tyrosine ratio being significantly different. Despite the decline of the P-T-ratio, normal
values of the separate amino acids were not obtained.
The mean tryptophan concentration was 35.5 µmol/l in the depressed patients vs. 45.6
µmol/l in the controls (p<0.0005). After treatment, the tryptophan level increased non-
significantly to 38.7 µmol/l. Psychotic depressed patients had a mean tryptophan level of
35.3 µmol/l rising to 39.6 µmol/l after ECT. The group that responded to treatment had an
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Table 1. 
Biopterin, neopterin, P-T-ratio and tryptophan-ratio before and after a course of ECT in 20
severely depressed patients compared to 29 healthy controls
Total Total Controls 
pre-treatment (n=20) post-treatment (n=20) (n=29)
biopterin(nmol/l) 5.7   (1.3)     p=0.002 6.3 (1.4) 7.0 (1.4)
neopterin (nmol/l) 21.7 (8.2)  23.6 (8.2)       p=0.03 19.6 (6.5)
P-T-ratio 1.0   (0.1)     p=0.001 0.9 (0.1)         p<0.0005 0.9 (0.2)
tryptophan 35.5 (9.0)     p<0.0005 38.7 (7.7) 45.6 (6.1)
LNAA 489.7 (99.2) 506.7 (107.8) 549.4 (107.1)
Trp-ratio 7.4   (2.0) 7.7 (1.0) 8.3 (1.1)
P-T-ratio = phenylalanine-tyrosine-ratio
Trp-ratio = tryptophan ratio
LNAA = large neutral amino acids; i.e. phenylalanine, tyrosine, isoleucine, leucine and valine.
Measures are presented as mean (standard deviation). P-values for pre-treatment measures give significance levels
compared to normal controls. P-values for post-treatment measures give significance levels compared to pre-treatment
measures. 
even lower tryptophan level of 33.9 µmol/l rising significantly after ECT to 38.3 µmol/l
(p=0.05).  For the tryptophan ratio, the same trend was visible, except for a non-signifi-
cantly lower ratio in the total group of patients compared to the controls. 
The five patients who used medication a few days before the last sample was taken were
distributed between the two subgroups: there were three responders and two non-
responders; one non-psychotic and four psychotic patients. Exclusion of these patients did
not essentially change the post-treatment results obtained. Without these patients post-
treatment biopterin was 6.0 (1.3) vs. 6.3 (1.4) nmol/l with these patients included. The
phenylalanine-tyrosine-ratio was 0.91 (0.14) vs. 0.89 (0.13) in the total group. This was
significantly lower than the pre-treatment value, as it was in the total group. For the
subgroup of responders, the same could be seen when these patients were excluded; a
significant lowering of the P-T-ratio (p<0.0005) and an increase in the tryptophan-ratio
(p=0.03).
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Table 2. 
Biopterin, neopterin, P-T-ratio and tryptophan-ratio before and after a course of ECT in 20
severely depressed patients, subdivided according to psychotic features.
psychotic psychotic non psychotic non psychotic
pre-treatment post-treatment pre-treatment post-treatment
(n=10) (n=10) (n=10) (n=10)
biopterin 5.5 (1.1)    p=0.04 6.5 (1.0)   p=0.03 5.9 (1.4)   p=0.04 6.1 (1.8)
(nmol/l)
neopterin 19.8 (3.8) 21.8 (4.6) 23.5 (10.9) 25.4 (10.7)
(nmol/l)
P-T-ratio 1.0 (0.2)     p=0.05 0.9 (0.1)   p=0.001 1.0 (0.1)   p=0.01 0.9 (0.2)   p=0.001
tryptophan 35.3 (11.1) p=0.02 39.6 (6.1) 35.7 (6.8) p=0.001 37.7 (9.3)
(µmol/l)
trp-ratio 7.0 (1.8)     p=0.05 7.7 (0.5) 7.8 (2.2) 7.7 (1.4)
P-T-ratio = phenylalanine-tyrosine-ratio
Trp-ratio = tryptophan ratio
Measures are presented as mean (standard deviation). P-values for pre-treatment measures give significance levels
compared to normal controls. Values of normal controls are mentioned in table 1. P-values for post-treatment measures
give significance levels compared to pre-treatment measures. 
Discussion
Our main finding is that the total plasma biopterin concentration is lower than normal
when studied in well selected, severely depressed inpatients, free of psychoactive
medication. In most patients, treatment with ECT was successful (75%) and this was
paralleled by an increase in biopterin levels. These findings were more pronounced in
depressed patients with mood-congruent psychotic features and in ECT-responsive
patients.
In children with phenylketonuria, it has been shown that the phenylalanine-tyrosine ratio is
a useful measure for phenylalanine hydroxylase activity, better than phenylalanine alone
(Rosenblatt and Scriver, 1968). As could be expected from the influence of biopterin on the
hydroxylating enzymes, we found a lower phenylalanine-tyrosine ratio after treatment,
indicating more hydroxylation of phenylalanine to tyrosine.
A lower pre-treatment concentration of tryptophan was observed both in the total group
of patients and in the responders. Only successful ECT treatment resulted in a significant
increase in tryptophan level. These seemingly contradictory results - successful ECT
treatment gives rise to higher biopterin levels and a consequently higher conversion of
tryptophan to serotonin - may be explained by a lower catabolism of tryptophan through
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Table 3. 
Biopterin, neopterin, P-T-ratio and tryptophan-ratio before and after a course of ECT in 20
severely depressed patients, subdivided according to response on treatment.
responders responders non responders non responders
pre-treatment post-treatment pre-treatment post-treatment
(n=10) (n=10) (n=10) (n=10)
biopterin 5.6 (1.2)   p=0.003 6.4 (1.0) 5.8 (1.7) 5.9 (2.5)
(nmol/l)
neopterin 21.8 (9.5) 24.3 (9.3) p=0.01 21.1 (1.9) 21.7 (3.6)
(nmol/l)
P-T-ratio 1.0 (0.1)   p=0.001 0.9 (0.1)   p<0.0005 1.0 (0.2) 0.9 (0.2)   p=0.001
tryptophan 33.9 (9.8) p<0.0005 38.3 (6.4) p=0.05 40.2 (4.3) p=0.005 37.7 (11.8)
(µmol/l)
Trp-ratio 6.6 (1.3)   p=0.005 7.7 (1.1)   p=0.003 9.8 (1.9) 7.7 (0.7)
P-T-ratio = phenylalanine-tyrosine-ratio
Trp-ratio = tryptophan ratio
Measures are presented as mean (standard deviation). P-values for pre-treatment measures give significance levels
compared to normal controls. Values of normal controls are presented in table 1. P-values for post-treatment measures
give significance levels compared to pre-treatment measures.
the kynurenine pathway, probably due to decreased cortisol levels. The tryptophan ratio
may also be a predictor for successful ECT treatment because this parameter was signifi-
cantly lower before treatment in the subgroup of responders and in the subgroup of
psychotic patients. However, the increase in this ratio after ECT was only significant for the
responders.
A limitation of our study is the use of medication before ECT was started. Perhaps the
wash-out period of 7 days was too short to rule out every influence on the biopterin and
amino acid metabolism. However, antidepressants seem to affect the plasma biopterin
levels in a limited way (Hashimoto, 1987). The differences between the subgroups cannot
be explained by such an influence because the same wash-out period was used for all
patients. Although only short-acting anaesthetics were administered before ECT, we
cannot rule out the possibility that this medication influenced the post-treatment
measures. Since the same standardised anaesthesia procedure was used on all patients, it
cannot explain the differences between the groups.  
Our findings are consistent with the results of Blair (Blair et al., 1984). Anderson and Abou-
Saleh also suggest a decrease in biopterin level with their finding of a higher neopterin-
biopterin ratio in depressed patients (Abou-Saleh et al., 1995; Anderson et al., 1992).
Patient selection, urinary measurements and concomitant use of medication could explain
conflicting results found in other studies. 
Neopterin levels in depressed patients differed non-significantly from levels in normal
controls. Our plasma neopterin values are difficult to compare with the results of Maes and
Dunbar. They found increased neopterin levels in depressed patients but did not use the
same, medication-resistant, severely depressed inpatient population as we did and, above
all, measured urinary neopterin (Dunbar et al., 1992; Maes et al., 1994). However, they are
indeed comparable with those of O'Toole who also studied plasma concentrations
(O'Toole et al., 1998). Perhaps this parameter is too non-specific to be a useful marker in
depression. 
Our results suggest that ECT influences biopterin metabolism, phenylalanine and tyrosine
metabolism and, hence, catecholaminergic function, and the availability of tryptophan as
can be concluded by the rise in the tryptophan-ratio. ECT apparently increases plasma
concentrations of biopterin, which in turn increases the metabolism of the amino acids
phenylalanine, tyrosine and tryptophan. This gives rise to interesting questions. Is effective
treatment with antidepressants also related to an increase in biopterin? Does a low
biopterin level predict a poor response to antidepressants? Or is ECT unique in its action on
biopterin, which in turn, improves synthesis of mainly tyrosine and, hence, improves
catecholaminergic function? More evidence that plasma biopterin can serve as a distinct
marker for the necessity to start ECT has to be provided.
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Effect of light therapy on biopterin, neopterin
and tryptophan in patients with seasonal 
affective disorder.
Rocco Hoekstra, Durk Fekkes, Ben J.M. van de Wetering, Lolke Pepplinkhuizen, Willem
M.A. Verhoeven. 
Abstract
The serotonergic system is believed to play a key role in the pathophysiology of seasonal
affective disorder (SAD). Tetrahydrobiopterin is an essential cofactor in the hydroxylation of
tryptophan and, therefore, in the synthesis of serotonin, while neopterin is known as
marker of cell-mediated immune activity. 
The present study was designed to measure levels of biopterin, neopterin and tryptophan
in plasma of 19 depressed patients with a history of SAD, before and after light therapy as
well as in a control group. In the group of patients a significantly lower plasma biopterin
and tryptophan level and a higher neopterin level was demonstrated. After light therapy,
the level of biopterin increased to that of the controls but lowered again in summer.
Neopterin concentrations remained on the same level after light therapy, whereas
tryptophan levels increased slightly after light therapy and reached normal values in
summer. 
It is concluded that the vulnerability for a depressive episode is enhanced by lowered levels
of biopterin that, however, in SAD becomes symptomatically manifest in the presence of
increased immune activity at the same time.
Reprinted from Psychiatry Research 2003;120:37-42, Copyright (Year), 
with permission from Elsevier.
 
Introduction
Seasonal affective disorder (SAD) is characterized by recurrent episodes of winter
depression with remission in the spring and summer. Patients with SAD differ from those
with a major depressive episode with melancholic features in both clinical presentation and
biological characteristics (Rosenthal et al., 1984). The efficacy of light therapy in SAD has
been generally accepted (Partonen and Lonnqvist, 1998). In The Netherlands the
prevalence of SAD is 3% (Mersch et al., 1999).
Although there is no consensus on the pathophysiology of SAD or on the mode of action of
light therapy, serotonergic mechanisms seem to play an important role. Evidence is found
not only for decreased activity of the serotonergic system, but therapeutic results of
serotonergic agents are also described (Neumeister et al. 2001).
Pteridines are compounds that occur in human as skin and eye pigments and act as
multifunctional cofactors such as folic acid and tetrahydrobiopterin (BH4) (Auerbach and
Nar 1997). BH4 is the essential cofactor for the enzyme tryptophan hydroxylase. This
enzyme hydroxylates tryptophan to 5-hydroxytryptophan, which is the rate-limiting step in
the biosynthesis of serotonin. In the pineal gland serotonin is converted to melatonin
(Levine, 1988). In addition, BH4 is an essential cofactor in the hydroxylation of
phenylalanine and tyrosine from which the catecholamines are synthesized. Furthermore,
this cofactor influences the release mechanism in nerve terminals of these neurotrans-
mitters (Wolf et al., 1991).  
BH4 is synthesized de novo from guanosine triphosphate (GTP) via the intermediate
dihydroneopterin triphosphate (H2NTP). The latter substance may also be converted to
neopterin, which is excreted in urine. The oxidative products of BH4 are dihydrobiopterin
and biopterin, which are also excreted in urine (Levine, 1988). 
Cytokine-mediated T-lymphocyte activation results in increased neopterin synthesis and its
release from macrophages. Therefore, neopterin can be used as a marker for cell-mediated
immune activation (Maes et al., 1994; Auerbach and Nar, 1997), and it has been suggested
subsequently that alterations in cell-mediated and humoral immune function may play a
role in the pathophysiology of depressive disorders (Maes et al., 1994). Support for this
idea stems from the observation of altered immunologic parameters, such as neopterin, in
depressed patients with SAD after monoamine depletion (Stastny et al., 2003). 
Biopterin has been found to be decreased in depression (Abou-Saleh et al., 1995;
Anderson et al., 1992; Coppen et al., 1989; Hoekstra et al., 2001). This could be explained
by assuming that the intermediate H2NTP is mainly converted to the immunologic marker
neopterin, more than to the cofactor BH4, resulting in less BH4-dependent hydroxylation
of tryptophan or tyrosine and consequently in decreased synthesis of serotonin, dopamine
and (nor) epinephrine. Since the pineal gland contains relatively high concentrations of
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BH4, less activity of this substance may in turn result in a decrease of melatonin levels
(Levine, 1988). 
The present study was designed to measure plasma levels of biopterin and neopterin, and
to investigate their relationship to plasma tryptophan in depressed patients with SAD,
before and after light therapy. Given the crucial role of biopterin in the synthesis of
serotonin and the diminished serotonergic activity in SAD, it was postulated that levels of
biopterin and tryptophan, the precursor of serotonin, would be lower in depressed
patients with SAD with an increase to normal values after light therapy. Since depression in
general, and particularly SAD, is associated with immune activation, an increase in
neopterin level before light therapy in depressed patients as compared to healthy controls,
with normalization after light therapy, was hypothesized. 
Methods
Subjects
The present study included 19 patients, one male and 18 females (mean age (±SD): 41.0
(±13.2) years) and was conducted in full accordance with the Helsinki principles. All had a
history of affective disorders with a seasonal pattern, and all but one had been treated
previously with light therapy. Excluded were the patients who were pregnant or suffered
from serious diseases known to influence pteridine metabolism, like infectious diseases,
autoimmune disorders, neoplastic disorders, Parkinson's disease or dementia. All patients
were free of any psychoactive medication for at least 4 weeks prior to experimentation.
Assessment
Severity of the depression was assessed with the Beck Depression Inventory (BDI), a self-
rating scale for depression. To ascertain the atypical symptoms of SAD, an addendum was
used (BDI-add), which is highly correlated with the Hamilton Rating Scale for Depression -
Add (Meesters and Jansen, 1993). This addendum includes item 12 (social withdrawal) and
17 (fatigability) from the BDI as well as items 16 (hypersomnia), 18 (appetite) and 19
(weight gain), which are inversely formulated. The presence of atypical symptoms was
defined by a score of at least 4 on the BDI-add. 
The period, in which light therapy was given ranged from 25 October to 8 March. Most
patients were referred in November. Eleven patients could be re-evaluated in July or August
of the following year. They did not differ in sex and age as compared to the 19 patients in
winter. 
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Light therapy
All patients received a standard regimen of 10 000 lux cool-white fluorescent light therapy
during 1 h on five consecutive mornings in our Outpatient Department. Light therapy was
applied between 08.30 and 10.00 h.  
Study design
On the first day of light therapy, an initial fasting venous blood sample was drawn. To
obtain reliable values for the amino acids, blood sampling was performed before 10.00 h.
Since light therapy was presented till Friday 10.00 h, the first possibility in practice to draw
the post-treatment blood sample before 10.00 h was 3 days after treatment. The BDI and
addendum were completed directly before light therapy and on the subsequent Friday
post-treatment. All patients were asked to return for a re-evaluation of both biochemical
and clinical parameters in the following summer period.
A total group of 31 healthy persons (16 males, 15 females; mean age (±SD): 36.8 (±8.3)
years) was used as a control group. Blood samples were taken from them in October.
Biochemical determinations
Immediately after the venapuncture plasma was prepared by a 20 min centrifugation step
at 2650 g and stored at -80 0C. The pteridines and the amino acids phenylalanine, tyrosine,
tryptophan, isoleucine, leucine and valine were measured by means of high performance
liquid chromatography (HPLC) as described elsewhere (Fekkes et al., 1995; Hoekstra et al.,
2001). The neopterin-biopterin (N-B) ratio was calculated by dividing neopterin by
biopterin concentration and is used as a measure for the production of BH4 (Barford et al.,
1984; Abou-Saleh et al., 1995). The tryptophan ratio was calculated as 100 times the
concentration of tryptophan divided by the summed concentration of the other large
neutral amino acids, i.e. phenylalanine, tyrosine, isoleucine, leucine and valine (Fernstrom
and Wurtman, 1972). 
Statistical analysis
Changes in plasma levels of biopterin, neopterin and tryptophan before vs. after light
therapy and before light therapy vs. summer were assessed with paired two-tailed t-tests.
Differences between depressed patients and controls were examined with independent
variables t-tests. The scores on the BDI-add in the depressed patients were correlated with
the biochemical parameters using the two-tailed Pearson correlation test. Data are
presented as mean ± S.D. Results were considered significant when p<0.05.
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Results
Immediately before the first light therapy session, a value of 22.9 (±12.1) on the BDI was
scored in the group of 19 patients. On the BDI-add, their score was 7.0 (±2.7). After light
therapy, these values were 9.7 (±8.0), and 2.8 (±2.2), respectively.  
Table 1 presents the main biochemical findings. As can be inferred, the concentration of
biopterin in the patients before light therapy was significantly lower than in the winter
control group and increased to the level of the control group after light therapy. The level of
neopterin in the patients was higher than in controls and did not change after light therapy.
In addition, the N-B ratio was higher in patients than in controls and decreased after
therapy. Finally, patients showed lower plasma levels of tryptophan, which remained low
during treatment. However, no differences between the groups were found regarding the
tryptophan ratio. The mean tryptophan concentration in winter (39.5 (±5.3) µmol/l) was
lower than in the summer (43.8 (±6.6) µmol/l) albeit this difference was not statistically
significant (Fig. 1). The latter was within the range of the control group.
Neopterin level and the N-B-ratio were positively correlated with the BDI-add score before
light therapy (r=-0.52, p=0.02 and r=-0.47, p=0.04, respectively). This association could
not be demonstrated for biopterin levels.   
Re-analysis by excluding the findings in the only male patient did not change the results;
neither could a sex-dependent difference in pteridine or amino acid concentrations be
demonstrated in the control group. 
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Table 1. 
Plasma levels (mean and SD) of biopterin, neopterin, tryptophan and derived ratios in patients
with SAD, measured in fall/winter before and after light therapy.
controls in fall before light therapy after light therapy
n=31 n=19 n=19
biopterin (nmol/l) 6.8 (1.4) # 6.0 (1.0) 6.8 (1.1)   §
neopterin (nmol/l) 18.2 (5.9) # 22.5 (7.6) 22.0 (5.6) 
N/B 2.8 (1.0) * 3.8 (1.4) 3.3 (0.9)    §
tryptophan (µmol/l) 44.8 (6.6) ¶ 39.5 (5.3) 41.4 (9.4)
trp-ratio 8.3 (1.1.) 8.3 (1.7) 8.3 (1.5)
# p=0.03
§ p<0.05
* p=0.005
¶ p<0.0005
All significance levels shown are compared to the values measured
before light therapy.
N/B is neopterin-biopterin-ratio 
Trp-ratio is tryptophan-ratio
Discussion
The present study demonstrated that in winter plasma biopterin and tryptophan levels in
depressed patients with SAD are lower as compared to controls, while the opposite was
found for plasma neopterin levels. After light therapy, biopterin was the only parameter
that normalized. With respect to biopterin, lower levels in summer were found in SAD
patients. Tryptophan levels did not alter in the various conditions. 
Because of its role in dopamine, (nor) epinephrine and serotonin metabolism, BH4 has
been studied in depressed patients. In most studies lower levels of biopterin were found in
plasma, urine or CSF (Abou-Saleh et al., 1995; Anderson et al., 1992; Coppen et al., 1989;
Hoekstra et al., 2001). It seems, therefore, plausible that decreased BH4 activity, because of
its role as a cofactor, could result in a reduced serotonin synthesis and consequently to
depressive symptoms.
The present observation of an increased neopterin level is in agreement with the findings in
SAD patients by Stastny et al. (2003) and supports the hypothesis that activation of the
immune system is involved in both SAD and depression in general (Dunbar et al., 1992;
Maes et al. 1994). The fact that neopterin as a marker of immune activation is enhanced
before and after light therapy suggests that an overactive cellular immune system may
serve as a trait marker in this patient group.
The decreased tryptophan level in SAD has not been reported previously to our knowledge
but is in line with the observation that tryptophan depletion may result in a relapse of
depressive symptoms in remitted patients with SAD (Neumeister et al., 1998) and with the
report by McGrath et al. (1990) that tryptophan may be effective in the treatment of this
disorder. 
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Figure 1. 
Plasma biopterin and tryptophan concentrations before light therapy (n=19), after light therapy (n=19) and in
summer (n=11) in depressed patients with seasonal affective disorder. Values are mean ± standard error.
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Involvement of the serotonin system in SAD can also be derived from data of various
studies, such as those on carbohydrate craving (Wallin and Rissanen, 1994), serotonin
receptor challenge (Schwartz et al., 1999), brain imaging (Willeit et al., 2000) and the
beneficial effects of serotonergic agents on the symptomatology of SAD (Lam et al., 1995). 
Interestingly, the observation in this study of low levels of biopterin and tryptophan before
light therapy, with an increase of biopterin after treatment, is comparable to our results
found before and after successful electroconvulsive therapy (Hoekstra et al., 2001). In the
latter study, however, we found no significant differences in plasma neopterin between
psychotic depressed patients and normal controls. These findings suggest not only
immune activation in a subgroup of depressed patients, but also a relationship between
biopterin and tryptophan and depressive symptomatology in general. 
Because the tryptophan ratios across the groups studied did not change, there is no
substantiation for decreased tryptophan levels in the CNS. The postulated impaired central
serotonergic activity in SAD patients is, therefore, more likely due to reduced availability of
the cofactor biopterin than to that of the precursor tryptophan. The increase of tryptophan
in summer may point to a lower activity of indoleamine dioxygenase, which in turn may
reflect a decreased cell-mediated immune activity (Fekkes and van Gool, 2003).
The biopterin level in patients with SAD in summer was lower than in normal controls and
also lower than after light therapy. This indicates an aberrant pteridine metabolism that is
apparently not sufficient to induce psychopathology. If, however, a second determinant
like increased immune activity, resulting in lower tryptophan levels, is present,
psychopathological symptoms may emerge. This phenomenon is illustrated in Fig. 1. 
Since it is not known whether peripherally measured pteridines reflect their intracerebral
levels, the results of the present study should be considered as preliminary. Although the
number of included patients is rather small, the significant differences between patients
and controls with respect to both neopterin and biopterin, may reflect actual changes in
pteridine metabolism. It is highly unlikely that subclinical activation of the immune system
with consequently increased neopterin levels did confound our results, since then both
patients and controls would have been affected in a similar way. 
In conclusion, the results of the present study support the hypothesis that pteridines may
be involved in the pathogenesis of SAD, via their influence on the serotonergic system. Oral
administration of BH4 in the treatment of SAD could further substantiate the role of
pteridines in this disorder.
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Bipolar mania and plasma amino acids:
Increased levels of glycine.
R. Hoekstra, D. Fekkes, A.J.M. Loonen, L. Pepplinkhuizen, S. Tuinier, W.M.A. Verhoeven. 
Abstract
Previous studies have suggested that the N-methyl-D-aspartate (NMDA) glutamate
receptor complex is implicated in the pathophysiology of several neuropsychiatric
disorders. Especially the glycine coagonist site of this receptor has been proposed as a
therapeutic target. It has been hypothesized that the NMDA receptor and the serotonergic
system, which function is compromised in affective disorders, are functionally coupled.
Furthermore, several studies suggest that peripheral levels of amino acids are associated
with psychotic symptomatology. We therefore measured plasma levels of glutamate,
glycine, tryptophan and the tryptophan ratio in 20 bipolar-I  patients during the manic
phase and at remission of symptomatology. Data were compared to a matched group of
healthy controls and a group of euthymic bipolar-I patients.
During the manic phase a significant increase of both glutamate and glycine was found,
that persisted at remission. Tryptophan and the tryptophan ratio were decreased in manic
patients. Subsequent analysis showed that changes in glutamate, tryptophan and
tryptophan ratio could be attributed to the use of anticonvulsants. The increased glycine,
however, was not related to the use of mood stabilizers. Although the exact relationship
between peripheral measures of amino acids e.g. glycine is not fully clear, the results of this
study suggest an involvement of glycine and/or its coagonist site of the NMDA-receptor in
a manic relapse of patients with a bipolar-I disorder. 
Published in European Neuropsychopharmacology 2006; 16:71-77
"This article is copyright protected. Any distribution without written consent 
from S. Karger AG, Basel is a violation of the copyright".
 
Introduction
Dysfunction of the glutamatergic neuronal systems has been postulated to be involved in
the pathogenesis of schizophrenia. Antagonism of the N-methyl-D-aspartate (NMDA)
glutamate receptor complex induces behavioural and cognitive deficits in normal subjects
with a broad range of central nervous system symptoms such as psychotic phenomena,
agitation and disorientation (Goff and Coyle, 2001). Enhancement of the NMDA receptor
activity has been demonstrated to induce symptomatic improvement in schizophrenia
(Coyle et al., 2002). Hypofunction of the NMDA-receptor complex is associated with
negative symptoms and cognitive deficits in patients with schizophrenia (Coyle et al., 2003). 
In addition to the binding site for the agonist glutamate, a glycine-coupled modulatory site
is present at the NMDA receptor complex (Javitt et al., 1999; Coyle et al., 2003). This
modulatory site must be occupied by glycine before glutamate is able to open the calcium
channel of the NMDA receptor (D'Souza et al., 2000; Coyle et al., 2003). Several studies
have described a relation between dysfunction of the glycine modulatory site and schizo-
phrenia. It is therefore considered to be a target for symptomatic treatment of patients
with schizophrenia (Coyle and Tsai, 2004; Heresco-Levy and Javitt, 2004; Javitt, 2004). 
Recently, increased plasma levels of glutamate were found in patients with schizophrenia as
compared to normal controls. Glutamate levels correlated significantly with negative
symptoms. In the same study it was shown that poor response to atypical antipsychotics is
associated with lower levels of peripheral serotonin (Van der Heijden et al., 2004).
Furthermore, it was demonstrated that the central availability of tryptophan, determined by
calculating the ratio between the plasma levels of tryptophan and the other large neutral
amino acids, is reduced in poor responders (Van der Heijden et al., 2005). With respect to
plasma concentrations of amino acids, lower levels of tryptophan have been demonstrated
repeatedly in patients with schizophrenia (Rao et al., 1990; Tortorella et al., 2001) and with
affective disorders (Lucca et al., 1995; Johnson et al., 2001; Neumeister, 2003). Although not
investigated extensively, plasma amino acid levels have been used as indirect measures for
central monoaminergic functionality (Finkelstein et al., 1982; Van der Mast and Fekkes,
2000).
In contrast to schizophrenia, the role of the NMDA receptor in mood disorders has been much
less studied, although recent preclinical and clinical research suggests that this receptor
complex may not only be involved in synaptic plasticity but may also be connected with the
long-term treatment of severe mood disorders (Krystal et al., 2002; Manji et al., 2003; Zarate
et al., 2003). Only few studies are known on the role of the NMDA receptor in specifically the
bipolar affective disorder. Increased plasma glutamate levels have been found in depressed
bipolar patients (Altamura, 1993). Furthermore, altered mRNA expression of glutamic acid
decarboxylase in hippocampal tissue of bipolar patients has been demonstrated (Heckers et
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al., 2002). Finally, elevated glutamate/glutamine levels in the frontal lobe and basal ganglia in
children with bipolar disorder have been suggestive for disturbances in the glutamate
metabolism (Castillo et al., 2000). One study focussed on bipolar mania and showed elevated
glutamate levels in the left dorsolateral prefrontal cortex (Michael et al., 2003).
Furthermore, mood stabilizers like lithium and valproic acid influence cerebral uptake and
release of glutamate (Dixon an Hokin, 1997, 1998; Zarate et al., 2002; Ketter and Wang,
2003; O'Donnell et al., 2003). In addition, antiglutamatergic agents like lamotrigine have
been demonstrated to have some beneficial effect on depressive symptoms in bipolar
disorders (Ernst and Goldberg, 2003). 
With respect to glycine in bipolar disorder, only studies from the eighties have demonstrated
an elevation of glycine in red blood cells of bipolar patients using lithium, which often
returned to the normal range after chronic treatment. Plasma glycine, however, was not
affected by lithium (Peselow et al., 1982; Rosenblatt et al., 1982). 
The role of serotonin (5-HT) in the pathogenesis of mood disorders has been widely studied.
However, the precise role of serotonin in bipolar mania is much less studied. Raised levels of 5-
hydroxyindoleacetic acid, the metabolite of serotonin, in cerebrospinal fluid of manic female
patients have been found (Swann et al., 1983), as well as diminished serotonin respon-
siveness after neuroendocrine challenge tests (Thakore et al., 1996) and increased platelet
uptake of serotonin (Meagher et al., 1990). Recent studies suggest a relationship between
glutamate receptors and the serotonergic system. Glutamate and 5HT-2A receptors are
anatomically and functionally coupled in e.g. the prefrontal cortex. In addition, glutamate
agonists activate 5-HT2A receptors, whereas serotonin activation results in inhibition of the
NMDA response (Pralong et al., 2002). 
The aim of this study was to investigate the plasma concentrations of amino acids related to
the NMDA receptor, i.e. glutamate and glycine, in patients with a manic episode in the course
of a bipolar affective disorder and after recovery from manic symptoms. To investigate the role
of the serotonergic system and its relation with the NMDA receptor, we also assessed the
central availability of the precursor amino acid of 5-HT by determining tryptophan and the
other large neutral amino acids, e.g. tyrosine, phenylalanine, valine, isoleucine and leucine.
Experimental procedures
The protocol was approved by the “Toetsingscommissie Patientgebonden
Wetenschappelijk Onderzoek” in Arnhem, The Netherlands, an officially recognized
Medical Ethics Committee. The project was performed in accordance with the Helsinki
declaration. Written informed consent was obtained from all patients.
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Subjects
The patients were recruited from the specialist outpatient department for bipolar disorders
of the Delta Psychiatric Teaching Hospital in Rotterdam, The Netherlands. All met the DSM-
IV criteria for a bipolar-I disorder. The inclusion criterion was a relapse of (hypo)manic
symptoms as assessed by the treating psychiatrist who used the elements of the
Comprehensive Psychiatric Rating Scale (CPRS; Åsberg et al., 1978) and the severity of
manic symptoms was measured by means of the Young Mania Rating Scale (YMRS).
Patients were consecutively recruited over a period of 24 months. Main demographic and
clinical characteristics, including the illness history, family load and treatment at inclusion
are presented in Table 1. Excluded were patients with clinically relevant somatic disorders of
any kind or comorbid DSM-IV axis-I disorders. 
The study included a total of twenty consecutively referred patients, 14 males and 6
females with a mean (± SD) age of 50.2 (± 13.8) years. All received maintenance treatment
with psychotropics (Table 1). During the manic phase treatment was adjusted according to
plasma levels and clinical status.
Instrument
The severity of manic symptoms was assessed with the 11-item YMRS that ranges from 0
till 60 (Young et al., 1978). The YMRS was completed at inclusion and when the patient
was judged to be clinically recovered. According to the factor analysis as described by
Gonzalez-Pinto et al. (2003) the YMRS has three dimensions: 'activation' (items 2
[increased motor activation, energy], 6 [accelerated speech] and 7 [altered thinking and
speech]), 'hedonism' (items 1 [euphoria], 3 [sexual interest], 4 [sleep] and 10 [appearance]),
and 'dysphoria' (items 5 [irritability], 9 [aggressive behaviour] and 11 [lack of insight]). 
Control subjects
Control values of amino acids were obtained from a large database of healthy subjects
from which an age and sex matched control group was composed (males: 14; females 6;
mean age ±SD 50.1 ±13.5 years). These values did not differ from those of the very large
control group from which they were extracted.
In order to investigate the effect of other psychotropics than lithium, a second control
group of 12 euthymic bipolar patients (mean age 40.2 ± 15.5; 8 males and 5 females) with
lithium prophylaxis as monotherapy was recruited from the same outpatient department
for bipolar disorders. Their demographic and clinical characteristics are depicted in Table 2.
Assessments were identical to those applied in the patient group and revealed no
symptoms of affective illness.
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Amino acid analysis
To measure amino acids a venous blood sample was drawn before 10 a.m. After remission
of the manic episode, as established with the YMRS, a second venous blood sample was
taken.
Immediately after the venapuncture, plasma was prepared by a 20 min centrifugation step
at 2650 g and stored at -80 0C. The large neutral amino acids: tryptophan (Trp),
phenylalanine, tyrosine, isoleucine, leucine and valine, and the amino acids glutamate,
glycine, serine, methionine, alanine and taurine were measured by means of high
performance liquid chromatography (HPLC) as described elsewhere (Fekkes et al., 1995;
Hoekstra et al., 2001). The tryptophan ratio (Trp-ratio) was calculated as 100 times the
concentration of Trp divided by the summed concentrations of the other large neutral
amino acids (Fernstrom and Wurtman, 1972). 
Statistical analysis
Changes in plasma levels of amino acids between the manic state and after recovery were
assessed with the paired two-tailed Student t-test. Differences between patients and
controls were examined with the two sample Student t-test. Change in YMRS scores, the
three dimensions and the plasma levels of the mood stabilizers lithium, valproic acid and
carbamazepine were correlated with the biochemical parameters using the Pearson
correlation test. Data are presented as mean (± SD). Results were considered significant
when p<0.05.
sex age duration number symptom severity of family load serum level 
of illness of relapses free interval previous episode of lithium
M 19 1 1 1 M3 + 0.29
M 37 15 >5 0.75 M4 + 0.72
M 35 13 >5 2 M4 - 0.73
F 57 27 2 9 M4 + 0.83
F 51 24 3 9 D3 - 0.95
F 42 14 5 4 D2 + 1.06
M 66 9 4 6 D3 - 0.66
F 23 2 3 1 M3 + 0.71
M 52 8 4 6 D2 - 0.99
F 30 9 6 3 M4 - 0.82
F 41 13 4 8 D3 - 0.67
M 54 21 >5 0.5 M2 - 0.63
Table 2. 
Demographic and clinical characteristics of the euthymic control group (n=12).
'Severity of last episode': D=depressive and M=manic; 1=slight, 2=moderate, 3=severe and 4=severe with psychotic
features (according to DSM-IV).
Results
The mean (±SD) score on the YMRS at inclusion was 21.7 (± 6.1), which is compatible with
moderately severe manic symptoms. After recovery, a score within the normal range was
found (1.6 ± 2.0). With respect to the three dimensions of the YMRS, the scores decreased
from 8.6 (± 1.7) to 0.1 (± 0.3) for 'activation', from 5.5 (± 2.3) to 0.5 (± 0.9) for 'hedonism'
and from 4.5 (± 2.7) to 0.6 (± 1.2) for 'dysphoria'.
At remission, the mean (±SD) plasma level of lithium was significantly higher than during
the manic episode (0.84 ± 0.13 versus 0.64 ± 0.2 mmol/l; p= 0.002). No changes in the
plasma concentrations of valproic acid and carbamazepine neither in the doses of antipsy-
chotics or other psychotropics were observed. This quite conservative medication policy
was possible because the patients got an intensive psychosocial coaching.
As can be inferred from table 3, the mean glutamate concentration in the group of manic
patients was significantly higher as compared to the group of healthy controls, with a
further increase at remission. In addition, a significant and persistent higher concentration
of glycine was found. Trp and Trp-ratio were significantly lower in the group of patients
under both conditions as compared to healthy controls.
Patients using valproic acid or carbamazepine had significantly higher glutamate levels
than the patients on lithium monotherapy only (52.3 ± 19.4 µmol/l (n=14) versus 34.0 ±
12.5 µmol/l; n=5; two sample t-test, p=0.049). In this group (n=14), Trp and its ratio as well
as glycine were lower (Trp 34.2  ± 10.3 µmol/l versus 43.6 ± 11.5 µmol/l; Trp-ratio 6.4  ± 1.8
versus 7.7  ± 0.4; glycine 254.6 ± 84.1µmol/l versus 342.4  ± 122.4 µmol/l).
By comparing the manic patients who used lithium only (n=5) with the euthymic bipolar
control group with lithium monotherapy (n=12), a significantly higher concentration of glycine
and a significantly lower value for the Trp-ratio were found during the manic phase (Table 4).
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Table 3. 
Plasma levels (SD) of amino acids in patients with bipolar mania (n=20) and matched controls (n=20).
glutamate (µmol/l) glycine (µmol/l) tryptophan (µmol/l) trp-ratio
manic phase 46.5 (19.4) 283.3 (102.7) 36.5 (10.9) 6.7 (1.6)
p=0.03 p=0.02 p=0.0005 p=0.002
at remission 56.8 (27.4)    288.8 (93.6) 37.9 (12.2) 6.3 (1.7)
p=0.04 p=0.69 p=0.53 p=0.24
healthy controls 36.1 (8.6) 224.0 (51.5) 47.8 (7.9) 8.2 (1.3)
P-values in row of 'manic phase' indicate comparison with healthy controls. P-values in row 'at remission' indicate
comparison to manic phase. 
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With respect to the relationship between symptomatology and amino acid levels in the
total group of manic patients, the plasma concentration of glutamate during the manic
phase was negatively correlated with the total YMRS-score (r=-0.5; p=0.04) and with the
dimension 'activation' (r=-0.6; p=0.005). In addition, the Trp-ratio was negatively
correlated with the dimension 'hedonism' (r=-0.4; p<0.05). No significant correlations
were found between the scores on the YMRS or its dimensions and any of the other amino
acids.
In the lithium subgroup (n=5), the shift from the manic phase to the remitted state resulted
in a slight decrease in the plasma concentration of glycine, which was correlated signifi-
cantly with the change in the dimension hedonism (r=0.468; p=0.04). 
Discussion
The present study with a group of bipolar-I patients with a manic relapse, demonstrates
increased plasma levels of the amino acids glutamate and glycine during both the manic
state and the remission phase as compared to the healthy control group. Furthermore,
both Trp and its ratio are decreased in this group. In addition, glycine levels are higher in the
subgroup with lithium monotherapy as compared to the euthymic bipolar control group
using lithium. 
The higher level of glutamate can be fully attributed to the use of anticonvulsants, an effect
that has also been demonstrated in mainly preclinical studies (Vriend and Alexiuk, 1996;
Dixon and Hokin, 1997; Petroff et al., 1999; O'Donnell et al., 2003). Thus, these findings
do not support an involvement of a glutamatergic dysfunction in mania. This is different
from the observations in patients with schizophrenia, in whom higher plasma glutamate
Table 4. 
Plasma levels (SD) of glutamate, glycine, tryptophan and tryptophan ratio in manic patients with lithium
(n=5) and euthymic controls (n=12).
glutamate (µmol/l) glycine (µmol/l) tryptophan (µmol/l) trp-ratio
manic phase 34.0 (12.5) 342.4 (122.4) 43.6 (11.5) 7.7 (0.4) 
p=0.74 p=0.049 p=0.47 p=0.02
at remission 39.4 (19.3) 319.2 (105.7) 46.4 (14.9) 7.7 (0.6)
p=0.56 p=0.60 p=0.55 p=0.96
euthymic controls 30.8 (19.1) 239.1 (75.6)  47.3(8.6) 9.8 (1.7)
P-values in row of 'manic phase' indicate comparison to euthymic controls. P-values in row of 'at remission' indicate
comparison to manic phase. 
levels do indicate an involvement of glutamatergic dysfunction in the pathophysiology of
schizophrenia (Macciardi et al., 1990; Goff and Coyle, 2001; Tortorella et al., 2001; Van der
Heijden et al., 2004).
With respect to plasma Trp and its ratio, the observed decreased values in the group of
bipolar patients compared to the control group, appears to be the result of treatment with
anticonvulsants. Similar observations have been reported by other investigators (Vriend
and Alexiuk, 1996; Verhoeven et al., 1999). Trp and Trp-ratio in the patient group on
lithium monotherapy were not different from those in the healthy control group. In the
group of euthymic bipolar patients, the Trp-ratio was found to be even higher than in the
control group (9.8 ± 1.7 vs. 8.2 ± 1.3; two sample t-test, p=0.008; Tables 3 and 4). This
difference is probably the result of chronic treatment with lithium. The exact mode of
action of lithium is unclear. Most studies concerning its influence on the serotonergic
system show an increased serotonin release after chronic treatment with lithium. Increased
central availability of the serotonin precursor Trp may indicate enhanced synthesis of
serotonin in the brain (Lenox and Hahn, 2000; Mahmood and Silverstone, 2001). The
negative correlation between the Trp-ratio and the dimension hedonism indicates a
possible influence of the cerebral availability of Trp to euphoria and other mood related
symptoms.
The main finding of the present study is the sustained increase of the plasma glycine
concentration in the group of patients with relapsing mania. The observed enhanced
values of glycine could not be attributed to the use of lithium, neither to the use of any
other mood stabilizing or psychotropic compound. This increase was no longer present in
stable euthymic patients with lithium monotherapy. The latter is in agreement with two
other studies (Rosenblatt et al., 1979; Rosenblatt et al., 1982), showing no effect of chronic
lithium treatment on the plasma levels of glycine. Whether long-term treatment with
valproic acid affects the plasma levels of glycine is unknown since the limited studies on this
topic stem from the eighties and concern either acute effects in epileptic patients (Verity et
al., 1983; Iinuma et al., 1988) or animal experiments (Mortensen et al., 1980). In this study
no effect of valproic acid on plasma glycine was found. The change in glycine was
correlated with the change in the dimension 'hedonism' from the YMRS, which forms the
classic symptom profile of mania.
Despite the limitations of this study, like relatively small patient groups and the use of
peripheral biochemical parameters, the observed increased plasma level of glycine may be
relevant since animal as well as human experiments have demonstrated that peripherally
administered glycine increases brain levels of this amino acid (Toth and Lajtha, 1986; Javitt
et al., 1999; D'Souza et al., 2000). Besides, in schizophrenic patients a dose-dependent
treatment response after glycine administration was reported (Javitt et al., 1994; Heresco-
Levy and Javitt, 2004). 
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In conclusion, the reported data on glycine suggest a role for the glycine coupled
modulatory site of the NMDA receptor not only in schizophrenia, but also in relapsing
mania. It could therefore be postulated that dysfunction of the NMDA receptor complex
plays a role in the vulnerability for the emergence of psychotic relapses in general.
Although the exact relationship between peripheral measures and central functionality is
not exactly clear, association studies like the present may be of heuristic value for the
pathophysiology of mental disorders.
Acknowledgements
The authors thank A.C.C. Voskuilen-Kooyman, E. Taal, J. Hoek and M. Waltmans for skilled
technical assistance. The authors are indebted to A.E.S. Sijben, M.A., Ph.D., for his
assistance in the statistical analysis. 
References
Altamura, C.A., Mauri, M.C., Ferrara, A., Moro, A.R., D'Andrea, G., Zamberlan, F.
(1993) Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J.
Psychiatry 150, 1731-1733.
Åsberg, M., Montgomery, S.A., Perris, C., Schalling, D., Sedvall, G. (1978) A compre-
hensive psychopathological rating scale. Acta Psychiatr. Scand. Suppl. 271, 5-27.
Castillo, M., Kwock, L., Courvoisie, H., Hooper, S.R. (2000) Proton MR spectroscopy in
children with bipolar affective disorder: preliminary observations. Am. J. Neuroradiol.
21, 832-838.
Coyle, J.T. Tsai G., Goff, D.C. (2002) Ionotropic glutamate receptors as therapeutic
targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disorders 1(2), 183-189.
Coyle, J.T., Tsai, G., Goff, D. (2003) Converging evidence of NMDA receptor
hypofunction in the pathophysiology of schizophrenia. Ann. N. Y. Acad. Sci. 1003, 318-
27.
Coyle, J.T., Tsai, G. (2004) The NMDA receptor glycine modulatory site: a therapeutic
target for improving cognition and reducing negative symptoms in schizophrenia.
Psychopharmacology 174, 32 - 38. 
D'Souza, D.C., Gil, R, Cassello, K., Morrissey, K., Abi-Saab, D., White, J., Sturwold, R.,
Bennett, A., Karper, L.P., Zuzarte, E., Charney, D.S., Krystal, J.H. (2000) IV glycine and
oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol
Psychiatry. 47(5), 450-62.
Dixon, J.F., Hokin, L.E. (1997) The antibipolar drug valproate mimics lithium in
stimulating glutamate release and inositol 1,4,5-triphosphate accumulation in brain
cortex slices but not accumulation of inositol monophosphates and biphosphates. Proc.
Natl. Acad. Sci. USA 94(9), 4757-60.
Dixon, J.F., Hokin, L.E. (1998) Lithium acutely inhibits and chronically up-regulates and
stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex.
Proc. Natl. Acad. Sci. USA 95, 8363-8368.
Ernst, C.L., Goldberg, J.F. (2003) Antidepressant properties of anticonvulsant drugs for
bipolar disorder. J. Clin. Psychopharmacol.23(2), 182-92.
Fernstrom, J., Wurtman, R. (1972) Brain serotonin content: physiological regulation by
plasma neutral amino acids. Science 178, 414-416.
Fekkes, D., Dalen van, A., Edelman, E., Voskuilen, A. (1995) Validation of the determi-
nation of amino acids in plasma by high-performance liquid chromatography using
automated derivatization with o-phtaldialdehyde. Journal of Chromatography B 669,
177-186.
Finkelstein, J.A., Chance, W.T., Fischer, J.E. (1982) Brain serotonergic activity and plasma
amino acid levels in genetically obese Zucker rats. Pharmacol. Biochem. Behav. 17(5),
939-944.
Goff, D.C., Coyle, J.T. (2001) The emerging role of glutamate in the pathophysiology
and treatment of schizophrenia. Am. J. Psychiatry 158, 1367-1377.
Gonzalez-Pinto, A., Ballesteros, J., Aldama, A., Perez de Heredia, J.L., Gutierrez, M.,
Mosquera, F., Gonzalez-Pinto, A. (2003) Principal components of mania. J. Affect.
Disord. 76(1-3), 95-102.
Heckers, S., Stone, D., Walsh, J., Shick, J., Koul, P., Benes, F.M. (2002) Differential
hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in
bipolar disorder and schizophrenia. Arch. Gen. Psychiatry 59, 521-529.
Heresco-Levy, U., Javitt, D.C. (2004) Comparative effects of glycine and D-cycloserine
on persistent negative symptoms in schizophrenia: a retrospective analysis. Biol.
Psychiatry 55, 165-71.
Hoekstra, R., van den Broek, W.W., Fekkes, D., Bruijn, J.A., Mulder, P.G.H.,
Pepplinkhuizen, L. (2001) Effect of ECT treatment on biopterin and large neutral amino
acids in severe, medication resistant depression. Psychiatry Res. 103 (2-3), 115-123.
Iinuma, K., Hayasaka, K., Narisawa, K., Tada, K., Hori, K. (1988) Hyperamino-acidaemia
and hyperammonaemia in epileptic children treated with valproic acid. Eur. J. Pediatr.
148(3), 267-9.   
Javitt, D.C., Zylberman, I., Zukin, S.R., Heresco-Levy, U., Lindenmayer, J.P. (1994)
Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry 151,
1234-1236.
Bipolar mania and plasma amino acids Chapter 5
86
Chapter 5 Bipolar mania and plasma amino acids 
87
Javitt, D.C., Balla, A., Sershen, H., Lajtha, A. (1999) Reversal of phencyclidine-induced
effects by glycine and glycine transport inhibitors. Biol. Psychiatry 45, 668-679.
Javitt, D.C. (2004) Glycine modulators in schizophrenia. Schizophr. Res. 66(2-3), 89-96.
Johnson, L., El-Khoury, A., Aberg-Wistedt, A., Stain-Malmgren, R., Mathe, A.A. (2001)
Tryptophan depletion in lithium-stabilized patients with affective disorder. Int. J.
Neuropsychopharmacol. 4(4), 329-336.
Ketter, T.A., Wang, P.W. (2003) The emerging differential roles of GABAergic and
antiglutamatergic agents in bipolar disorders. J. Clin. Psychiatry 64 (suppl 3), 15-20.
Krystal, J.H., Sancora, G., Blumberg, H., Anand, A., Charney, D.S., Marek, G., Epperson,
C.N., Goddard, A., Mason, G.F. (2002). Glutamate and GABA systems as targets for
novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 7 (suppl. 1), S71-
S80.
Lenox, R.H., Hahn, C-G. (2000) Overview of the mechanism of action of lithium in the
brain: fifty-year update. J. Clin. Psychiatry;  61 (suppl 9), 5-15.
Lucca, A., Lucini, V., Catalano, M., Smeraldi, E. (1995) Neutral amino acid availability in
two major psychiatric disorders. Prog. Neuropsychopharmacol Biol Psychiatry 19(4),
615-626.
Macciardi, F., Lucca, A., Catalano, M., Marino, C., Smeraldi, E. (1990) Amino acid
pattern in schizophrenia : some new findings. Psychiatry Res. 32, 63-68.
Mahmood, T., Silverstone, T. (2001) Serotonin and bipolar disorder. J. Affect. Disord. 66,
1-11.
Manji, H.K., Quiroz, J.A., Sporn, J., Payne, J.L., Denicoff, K., Gray, N.A., Zarate Jr., C.A.,
Charney, D.S. (2003) Enhancing neuronal plasticity and cellular resilience to develop
novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 53, 707-
742.
Meagher, J.B., O'Halloran, A., Carney, P.A., Leonard, B.E. (1990) Changes in platelet 5-
hydroxytryptamine uptake in mania. J. Affect. Disord. 19(3): 191-6.
Michael, N., Erfurth, A., Ohrmann, P., Goessling, M., Arolt, V., Heindel, W., Pfleiderer, B.
(2003) Acute mania is accompanied by elevated glutamate/glutamine levels within the
left dorsolateral prefrontal cortex. Psychopharmacology 168, 344-346.
Mortensen, P.B., Kolvraa, S., Christensen, E. (1980) Inhibition of the glycine cleavage
system: hyperglycinemia and hyperglycinuria caused by valproic acid. Epilepsia 21(6),
563-9.
Neumeister, A. (2003) Tryptophan depletion, serotonin, and depression: where do we
stand? Psychopharmacol. Bull. 37(4), 99-115.
O'Donnell, T., Rotzinger, S., Ulrich, M., Hanstock, C.C., Nakashima, T.T., Silverstone, P.H.
(2003) Effects of chronic lithium and sodium valproate on concentrations of brain amino
acids. Eur. Neuropsychopharmacol. 13(4), 220-7.
Peselow, E.D., Deutsch, S.I., Stanley, M., Banay-Schwartz, M., Virgilio, J., Fieve, R.R.
(1982) Erythrocyte glycine in depressed, hypomanic, and euthymic bipolar patients
treated with lithium carbonate. Psychopharmacology 78 (4), 314-6.
Petroff, O.A., Rothman, D.L., Behar, K.L., Hyder, F., Mattson, R.H.. (1999) Effects of
valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in
patients with refractory complex partial seizures. Seizure 8 (2), 120-7.
Pralong E., Magistretti P., Stoop, R. (2002) Cellular perspectives on the glutamate-
monoamine interactions in limbic lobe structures and their relevance for some
psychiatric disorders. Prog. Neurobiol. 67(3) 173-202.
Rao, M.L., Gross, G., Strebel, B., Braunig, P., Huber, G., Klosterkötter, J. (1990) Serum
amino acids, central monoamines, and hormones in drug-naive, drug-free, and
neuroleptic-treated schizophrenic patients and healthy subjects. Psychiatry Research
34, 243-257.
Rosenblatt, S., Gaull, G.E., Chanley, J.D., Rosenthal, J.S., Smith, H., Sarkozi, L. (1979)
Amino acids in bipolar affective disorders: increased glycine levels in erythrocytes. Am. J.
Psychiatry 136(5), 672-4.
Rosenblatt, S., Leighton, W.P., Chanley, J.D. (1982) Elevation of erythrocyte glycine
levels during lithium treatment of affective disorders. Psychiatry Res. 6(2), 203-14.
Swann, A.C., Secunda, S., Davis, J.M., Robins, E., Hanin, I., Koslow, S.H., Maas, J.W.
(1983) CSF monoamine metabolites in mania. Am. J. Psychiatry 140(4), 396-400.
Thakore, J.H., O'Keane, V., Dinan, T.G. (1996) D-fenfluramine-induced prolactin
responses in mania: evidence for serotonergic subsensitivity. Am J Psychiatry
153(11):1460-3.
Tortorella, A., Monteleone, P., Fabrazzo, M., Viggiano, A., De Luca, L., Maj, M. (2001)
Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine.
Neuropsychobiology 44, 167-171.
Toth, E., Lajtha, A. (1986)  Antagonism of phencyclidine-induced hyperactivity by
glycine in mice. Neurochem. Res. 11(3), 393-400.
Van der Heijden, F.M.M.A., Tuinier, S., Fekkes, D., Sijben, A.E.S., Kahn, R.S., Verhoeven,
W.M.A. (2004) Atypical antipsychotics and the relevance of glutamate and serotonin.
Eur. Neuropsychopharmacology 14 (3), 259-65.
Van der Heijden, F.M.M.A., Fekkes, D., Tuinier, S., Sijben, A.E.S., Kahn, R.S., Verhoeven,
W.M.A. (2005) Amino acids in schizophrenia: evidence for lower tryptophan availability
during treatment with atypical antipsychotics? J. Neural Transm 112, 577-585.
Van der Mast, R.C., Fekkes, D. (2000) Serotonin and amino acids; partners in delirium
pathophysiology? Semin. Clin. Neuropsychiatry 5(2), 125-131.
Verhoeven, W.M.A., Tuinier, S., van den Berg, Y.W.M.M., Coppus, A.M.W., Fekkes, D.,
Pepplinkhuizen, L., Thijssen, J.H.H. (1999) Stress and self-injurious behavior; hormonal
Bipolar mania and plasma amino acids Chapter 5
88
and serotonergic parameters in mentally retarded subjects. Pharmacopsychiat. 32, 13-
20.
Verity, C.M., Applegarth, D.A., Farrell, K., Kirby, L.T. (1983) The influence of anticon-
vulsants on fasting plasma ammonia and amino acid levels. Clin. Biochem. 16(6), 344-5.
Vriend, J.P., Alexiuk, N.A. (1996) Effects of valproate on amino acid and monoamine
concentrations in striatum of audiogenic seizure-prone Balb/c mice. Mol. Chem.
Neuropathol. 27 (3), 307-24. 
Young, R.C., Biggs, T., Ziegler, E., Meyer, D.A. (1978) A rating scale for mania: reliability,
validity and sensitivity. Br. J. Psychiatry 133, 429-435.
Zarate, C.A., Quiroz, J., Payne, J., Manji, H.K. (2002) Modulators of the glutamatergic
system: implications for the development of improved therapeutics in mood disorders.
Psychopharmacol. Bull. 36(4), 35-83.
Zarate Jr., C.A., Du, J., Quiroz, J., Gray, N.A., Denicoff, K.D., Singh, J., Charney, D.S.,
Manji, H.K. (2003) Regulation of cellular plasticity cascades in the pathophysiology and
treatment of mood disorders: role of the glutamatergic system. Ann. N. Y. Acad. Sci.
1003, 273-91.
Chapter 5 Bipolar mania and plasma amino acids 
89
Bipolar mania and plasma amino acids Chapter 5
90

General Discussion Chapter 6
92
General Discussion
1. The history and diagnosis of affective disorders
All patients included in the studies described in this thesis were suffering from various types
of affective disorder: bipolar-I disorder, seasonal affective disorder and severe major
depressive disorder with psychotic features. Although these clinical affective syndromes
are distinct entities from the phenomenological viewpoint, it is by no means clear whether
a distinct pathophysiology and aetiology corroborates their clinical differentiation. 
The discussion about the symptomatic delineation of affective disorders goes back to the
pre-Hippocratic area. In that time morbid states of depression and exaltation were known to
the physicians. Hippocrates was the first to delineate melancholia, mania and paranoia but
it is an anachronism to suppose that these words have the same meaning as the current
disease entities. Our current notions about depression and mania date from the second half
of the 19th century when the anatomo-clinical model of disease was embraced and
subjective experiences were included in the symptomatology of mental disorders (Berrios,
1995). Until then, melancholia was used as a collective term for insanity states with a few
delusions. Thus, states of non-psychotic depression would not have been called
melancholia. In 1838 Jean-Etienne-Dominique Esquirol described the so called lypemania
that can be considered as an early designation of a state characterized by debilitating and
overwhelming sadness with delusions fixed on specific topics. Subsequently Billot (1856)
defined lypemania on the basis of sad delusions and disordered affect. Berrios (1995) states
that lypemania is an example of what historians would call a bridge category between the
old notion of melancholia and the new conceptualization of a disorder of affect. As
reviewed by Angst and Marneros (2001), the German psychiatrist Wilhelm Griesinger
described in 1845 the change from melancholia to mania which he considered to be usual.
The French psychiatrist Jean-Pierre Falret firstly described in 1851 the so-called folie
circulaire, characterized by a continuous cycle of depression, mania and free intervals of
various lengths. The description of this disease entity was supported by Karl Kahlbaum in his
publication from 1882 about cyclisches Irresein. Subsequently, Emil Kraepelin (1893)
grouped depressive and circular forms of depressive disorders in his concept of manic
depressive illness. Kraepelin's unification of all affective disorders was challenged by the
German psychiatrist Carl Wernicke (1906) and his fellow Karl Kleist who differentiated
several types of affective syndromes, including unipolar and bipolar affective disorders.
Their concepts were in 1957 completed by Karl Leonhard who classified the phasic
psychoses into the pure and the polymorphic phasic disorders. Bipolar affective disorders
and cycloid psychoses were classified within the polymorphic phasic psychoses and unipolar
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depressive disorder within the pure phasic psychoses. In the mid sixties of the last century,
both Jules Angst and Carlo Perris independently published their papers on the nosological
differentiation of unipolar and bipolar affective disorders (Angst and Perris, 1968).
The history of the seasonal affective disorder is rather obscure. Although a seasonal rhythm
of mental disorders was already described in the second half of the 19th century by the
German and the French psychiatrists, it lasted until the eighties of the past century before
the criteria for this subtype of depressive disorder were formulated by Rosenthal and co-
workers (Rosenthal et al., 1984; Wehr and Rosenthal, 1989). Since then the operational
criteria have undergone several changes and include vegetative symptoms that are the
reverse of classical depressive vegetative symptoms e.g. increased sleep and appetite
(Magnusson and Partonen, 2005).
The various types of affective disorder have been included in the current classification
systems, the Diagnostic and Statistical Manual of Mental Disorders (DSM) and the
International Classification of Diseases (ICD). The seasonal affective disorder was firstly
incorporated in the DSM-III-R in 1987 as a specifyer of the longitudinal course of several
types of affective disorders. In the DSM system, a 'psychotic depression' is a major
depressive episode with a severity specifyer 'with psychotic features that can be mood
congruent or incongruent', whereas the category bipolar-I disorder describes an affective
disorder with at least one manic episode.
In order to include homogenous patient groups in the various studies as described in this
thesis, patients had to meet the strict DSM-IV criteria for bipolar-I disorder, major
depressive disorder with a seasonal pattern and severe depressive disorder with
melancholic and/or psychotic features. 
2. Biochemical parameters
2.1. Pterins
Measurement of neopterin levels with HPLC techniques is reliable and valid. Neopterin is
the excretion product of 2,3-dihydroneopterine triphosphate. Cytokines like interferon-
gamma stimulate the pterin synthesis through activation of GTP cyclohydrolase. In
macrophages the enzyme 6-pyruvoyl tetrahydropterin synthase is not present. Therefore,
the neopterin level is an accepted measure for cell-mediated immune activity (Levine,
1988; Dunbar et al., 1992; Maes et al., 1994; Murr et al., 2002).
A decrease of neopterin could be indicative for a general deactivation of the pterin
metabolism resulting in less synthesis of tetrahydrobiopterin. Direct measurement of the
active compound tetrahydrobiopterin is not feasible, because of its instability. After blood
drawing, this substance is rapidly broken down to biopterin and pterin, which results in an
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underestimation of the plasma levels of total biopterin (Fiege et al., 2004). Although
several investigators have assessed total biopterin using comparable methods (e.g.
Hashimoto et al., 1987; Knapp and Irwin, 1989; Anderson et al., 1992; Chrapko et al,
2004), measurement of total biopterin is considered to be a less valid indicator of the actual
activity of BH4. A more precise measure is the Phe-Tyr ratio, which reflects the BH4-
dependent hydroxylating activity (Anderson et al., 1994). The Cit-Arg ratio is also indicative
for the activity of BH4 (Finkel et al., 1996; Fekkes et al., 2007). These amino acids, however,
are also involved in other metabolic pathways, which makes this ratio less reliable.
2.2. Nitric oxide
Nitric oxide (NO) has a widespread function in the CNS and its synthesis is catalyzed by
endothelial and neuronal NOS. After immune activation another isoform of NOS is
induced, viz. iNOS, resulting in NO synthesis (Prast and Philippu, 2001; Akyol et al., 2004;
Bernstein et al, 2005). Since NO plays a stimulating and mediating role in several neuronal
processes, it is hypothesized to be implicated in various neuropsychiatric disorders (Prast
and Philippu, 2001; Akyol et al, 2004). 
Decreased activity of endothelial NOS may result in vasoconstriction and lowering of
cerebral blood flow (Watkins, 1995; Li and Forsterman, 2000; Willmot et al, 2005). 
Decreased activity of neuronal NOS has been implicated in a number of pathophysiological
mechanisms. It may result in less release of mostly excitating neurotransmitters and in a
disturbed balance of multiple cellular events. NO influences the activity of transcription
factors, modulates upstream signalling cascades and affects both the stability and
translation of mRNA (Bernstein et al., 2005). Targets of NO include guanylate cyclase, G
proteins and amines, and neuropeptide release and transport (Akyol et al., 2004). Several
of these processes are thought to be important in the regulation of mood (Akyol et al,
2004; Manji et al., 2000). Furthermore, NO is hypothesized to play a role in structural
changes in the central nervous system through an influence on long term potentiation and
long term desensitization, In addition, NO affects  the NMDA receptor complex and
influences  the HPA-axis (Prast and Philippu, 2001; Bernstein et al, 2005; Akyol, 2004;
Riedel, 2000). 
2.3. Pterins and nitric oxide
The metabolism of pterins and nitric oxide is closely interrelated. The synthesis of NO from
arginine is not only catalyzed by the enzyme NOS, but is also dependent on the presence of
BH4 as a cofactor (Mayer and Werner, 1995; Koshimura et al., 2000). Thus, lower BH4
levels may result in decreased synthesis of NO. Moreover, if NOS is not fully saturated with
BH4, potentially neurotoxic free radicals may be formed (Koshimura et al., 2000;
Nakamura et al, 2001).
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3. Main findings
Chapter 2 deals with bipolar-I patients who were compared with patients with either a
major depressive disorder with melancholic features or with a seasonal pattern and with
healthy controls. Manic-, depressed- and euthymic bipolar patients showed a decreased
level of neopterin, which was correlated with a lower ratio of citrulline and arginine,
indicative for less synthesis of NO. After symptomatic recovery the lowering of both
neopterin and the citrulline-arginine ratio persisted. 
These findings suggest that the NO and pterin metabolism play a role in a specific vulnera-
bility of bipolar-I patients to develop mood changes. 
Chapter 3 focuses on a group of patients with severe treatment-resistant depression with
psychotic and/or melancholic features. In comparison to healthy controls, these patients
showed before treatment significantly lower levels of biopterin, a higher Phe-Tyr ratio -
indicative for a lower BH4 dependent hydroxylation -, and significantly lower plasma levels
of tryptophan. Plasma levels of neopterin, however, were not different.
After treatment with electroconvulsive therapy (ECT), in the psychotic depressed patients
an increase of biopterin was found and a decrease of the Phe-Tyr ratio. Responders to ECT
showed an increase of both tryptophan and the tryptophan ratio.
These findings may be suggestive for a role of the hydroxylase function of tetrahydro-
biopterin and probably of NO in the pathophysiology of severe major depression and the
treatment effect of ECT.
Chapter 4 describes a group of patients with a major depression with a seasonal pattern. As
compared to normal controls, the patients showed increased levels of neopterin and a
decrease of biopterin and tryptophan. After light therapy, the higher level of neopterin
persisted. In addition, an increase of biopterin and tryptophan was found. In summer,
tryptophan levels normalized, whereas biopterin concentrations lowered again. 
These results (lowering of biopterin) were originally interpreted as a vulnerability factor for
the occurrence of a symptomatic period of this subtype of depression. The results of later
studies, however, indicated that biopterin is a less precise measure of BH4 activity. The
higher neopterin levels suggest increased cell-mediated immune activity in this disorder.
Chapter 5 investigates bipolar-I patients with a manic episode in comparison with healthy
controls and bipolar-I patients in full remission. In the manic phase, a significant increase in
glycine was demonstrated that persisted after remission of manic symptoms, suggestive
for in involvement of the NMDA receptor complex in vulnerability for mania. Changes in
other biochemical parameters could be attributed to the use of anticonvulsants.
In Summary:
The results of these studies reflect the functional activity of the essential cofactor BH4 in
different patient groups with affective disorders as measured with indirect and relatively
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simple biochemical methods. Neopterin, Phe-Tyr ratio, Cit-Arg ratio and the levels of the
precursors and metabolites of dopamine and serotonin are all somehow related to BH4
activity. The observed disturbances suggest the presence of a biochemical endophenotype
in affective disorders. This thesis comprises four studies with a relative small number of
patients who were treated in normal daily clinical practice of a general psychiatric hospital.
Although the research setting itself generates limitations, these findings demonstrate that
with modest tools a contribution can be given to the scientific development in psychiatry.
4. Future research
In search for the biochemical endophenotype of affective disorders it could be of great
interest to investigate the role of pterines and BH4 in other psychiatric diseases with an
affective component such as schizoaffective and certain other psychotic disorders. To
further investigate the role of pterines in the pathophysiology of affective disorders,
interfering with this biochemical pathway, e.g. by oral administration of BH4, and close
monitoring of changes in symptomatology might contribute to the development of novel
therapeutic approaches. Since a polymorphism of the gene that encodes for GTPCH, the
enzyme that is involved in the biosynthesis of BH4, has been demonstrated in a very limited
number of recent studies to be associated with affective disorders, it is worthwhile to
pursue this line of research in psychiatric disorders with affective symptoms.
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Summary
In this thesis patients with various affective disorders are described. Patients with a bipolar-
I disorder, which is characterized by prominent affective symptomatology, were
investigated. This disorder is characterized by cyclic lowered and elevated mood. In
addition, patients with a severe, often psychotic, depressive disorder were studied as well
as depressed patients with a seasonal pattern.
The central issue of this thesis deals with the role of pterins and nitric oxide (NO) in the
pathophysiology of various types of affective disorders. NO is thought to be related to
mood disorders because of its vascular and neuronal functional implications. The synthesis
of NO is catalyzed by the enzyme nitric oxide synthase for which tetrahydrobiopterin is
required as cofactor. In the synthesis of dopamine, norepinephrine and serotonin this
cofactor is also required which underlines the putative role of this compound in neuropsy-
chiatric disorders. In chapter 1 the literature is reviewed. 
Chapter 2 investigates the relationship between bipolar affective disorder and the pterin
and NO metabolism. Bipolar-I patients were compared to those with a major depressive
disorder with melancholic and/or psychotic features, with a seasonal affective disorder and
with healthy controls. Irrespective the clinical state of the bipolar-I patients a lower concen-
tration of both neopterin and the ratio of citrulline and arginine was found. In addition,
these parameters were positively correlated. These results suggest that the bipolar-I
disorder can be differentiated biochemically from other affective disorders. The lower ratio
of citrulline and arginine reflects a decreased synthesis of NO. The decrease of neopterin is
probably related to a lowered synthesis of pterins. These data suggest that NO and pterin
metabolism are associated with the vulnerability for bipolar mood changes.
Chapter 3 describes the study on pterins and related amino acids in patients with major
depression with melancholic and/or psychotic features. Medication-free patients were
compared to healthy controls. Patients showed lower biopterin levels and an increase of
the ratio of phenylalanine and tyrosine as well as a lower plasma tryptophan level. After
electroconvulsive therapy (ECT) an increase of biopterin and a decrease of the
phenylalanine tyrosine ratio were found in depressed patients with psychotic features,
suggestive for an increased activity of the cofactor tetrahydrobiopterin. Responders to ECT
showed an increase of tryptophan and tryptophan ratio. These findings suggest a
disturbed pterin metabolism in this group.
Chapter 4 describes a study in patients with seasonal affective disorder.  Plasma levels of
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pterins and related amino acids were determined and compared to those obtained in
healthy controls. A decrease of biopterin and tryptophan concentrations was found as well
as an increase of neopterin. After treatment with light therapy the latter persisted, whereas
the levels of biopterin and tryptophan increased. During the asymptomatic summer
season, tryptophan normalized and biopterin decreased. This persistent increase of
neopterin reflects enhanced cell mediated immune activity that, together with lower
tryptophan levels may be associated with depressive symptoms in winter.
Chapter 5 focuses on bipolar-I manic patients who were compared with healthy controls
and euthymic bipolar-I patients. The patients in a manic phase showed an increase of the
plasma glycine levels which may indicate an involvement of the NMDA receptor complex in
the pathophysiology of mania.
Chapter 6 discusses the main findings of this thesis. The delineation of the various affective
disorders in history is outlined.  In the present studies, the strict DSM-IV criteria for bipolar-
I disorder, major depression with melancholic and/or psychotic features and seasonal
affective disorder were applied.
The plasma level of neopterin seems to be a reliable and valid measure of the pterin
metabolism. A decrease of neopterin suggests a general reduction of the pterin
metabolism, resulting in a reduced synthesis of NO and of neurotransmitters such as
dopamine and serotonin. The various abnormalities in the biochemical parameters most
probably reflect a biochemical endophenotype in the different affective disorders. 
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Samenvatting
Dit proefschrift gaat over patiënten met verschillende stemmingsstoornissen. Patiënten met
een bipolaire stoornis type I, een aandoening waarbij bij uitstek de affectieve symptoma-
tologie centraal staat, werden onderzocht. Deze psychiatrische ziekte wordt gekenmerkt
door het voorkomen van zowel een verlaagde als een verhoogde stemming en heeft een
karakteristiek episodisch beloop. Voorts zijn patiënten met ernstige, veelal psychotisch
depressieve symptomatologie onderzocht. Patiënten met zogenaamde atypische
depressieve klachten en een seizoensgebonden patroon zijn als aparte subgroep onderzocht.
De centrale vraag van dit proefschrift behelst de mogelijke betekenis voor de pathofysi-
ologie van zowel pterines als stikstofoxide (NO) in de verschillende typen stemmingsstoor-
nissen. NO wordt in toenemende mate in verband gebracht met affectieve stoornissen
vanwege de invloed op zowel vasculaire als neuronale functies. Het enzym stikstofoxide
synthase heeft tetrahydrobiopterine als cofactor nodig om NO te kunnen synthetiseren.
Deze cofactor is daarnaast essentieel voor de synthese van dopamine, noradrenaline en
serotonine en wordt daarom ook in verband gebracht met de pathofysiologie van
neuropsychiatrische aandoeningen. In hoofdstuk 1 wordt de literatuur over dit onderwerp
kritisch beschouwd.
Hoofdstuk 2 onderzoekt de samenhang tussen een bipolaire stemmingsstoornis en het
pterine metabolisme. De patiënten met een bipolaire stoornis type I werden vergeleken
met patiënten met een depressieve stoornis met vitale en vaak psychotische kenmerken,
met patiënten met een seizoensgebonden depressie en met gezonde controles. Ongeacht
de klinische status van de bipolaire patiënt, d.w.z. zowel tijdens de depressieve, manische
als euthyme fase, werd een verlaging van neopterine en van de citrulline-arginine ratio
gevonden. Deze parameters waren bovendien positief gecorreleerd . 
Deze bevindingen maken duidelijk dat op biochemisch niveau een onderscheid kan
worden gemaakt tussen de bipolaire stoornis en andere affectieve aandoeningen. De
verlaging van de citrulline-arginine ratio wijst op een verminderde synthese van NO. De
verlaging van neopterine zou kunnen betekenen dat het verlaagde pterinemetabolisme
hieraan gerelateerd is of zelfs oorzakelijk verbonden. Mogelijk is het veranderde NO
metabolisme geassocieerd met een verhoogde kwetsbaarheid voor bipolaire
stemmingswisselingen. 
Hoofdstuk 3 beschrijft het onderzoek naar pterinen en daaraan gerelateerde aminozuren bij
patiënten met een psychotische depressie. Medicatievrije patiënten werden vergeleken met
gezonde controles. Bij de patiënten werd een verlaging van biopterine gevonden en een
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daarmee samenhangende verhoging van de phenylalanine-tyrosine ratio. Voorts bleek het
plasma tryptofaangehalte verlaagd te zijn. Het effect van behandeling met electrocon-
vulsieve therapie (ECT) op deze parameters werd eveneens onderzocht. Vooral bij de
psychotisch depressieve patiënten werd een toename van biopterine en een verlaging van
de phenylalanine-tyrosine ratio gevonden, hetgeen wijst op een toegenomen activiteit van
de cofactor tetrahydrobiopterine. Daarnaast werd een verhoging van tryptofaan en de
tryptofaan ratio vastgesteld bij patiënten die verbeterden op ECT. 
Deze bevindingen wijzen op een verstoring van het pterinemetabolisme bij ernstig
depressieve patiënten. Behandeling met ECT is mogelijk van invloed op de synthese van
pterines en wellicht ook op de vorming van NO. 
Hoofdstuk 4 beschrijft een studie bij patiënten met een seizoensgebonden depressie.
Plasmaconcentraties van pterines en daaraan gerelateerde aminozuren werden
vergeleken met die van gezonde controles. Naast een verlaging van biopterine en
tryptofaan werd een toename van neopterine gevonden. Na behandeling met
lichttherapie bleef deze toename aanwezig, terwijl de concentraties van biopterine en
tryptofaan stegen. Gedurende de asymptomatische zomerperiode trad een verdere
normalisering van het tryptofaangehalte op, terwijl biopterine laag bleef. De persisterende
verhoging van neopterine hangt mogelijk samen met een toegenomen celgemedieerde
immuunactiviteit die, tezamen met een verlaging van tryptofaan, in de winter gepaard
gaat met depressieve klachten. 
Hoofdstuk 5 richt zich op patiënten met een bipolaire-I stoornis. De patiënten werden
vergeleken met gezonde controles en euthyme bipolaire-I patiënten. De patiënten in een
manische fase vertoonden een toegenomen plasma glycine concentratie, hetgeen wijst op
een betrokkenheid van het NMDA receptor complex in de pathofysiologie van de manie. 
Hoofdstuk 6 bespreekt de belangrijkste bevindingen uit dit proefschrift. Vanuit historisch
perspectief wordt aangegeven hoe affectieve stoornissen een aparte nosologische
categorie zijn geworden. De strikte DSM-IV criteria voor de bipolaire stoornis, ernstige
depressieve stoornis met of zonder psychotische kenmerken en de depressieve stoornis
met seizoensgebonden patroon zijn gehanteerd bij de selectie van de patiënten voor dit
onderzoek. 
Van de pterines is het gehalte aan neopterine de meest betrouwbare maat. Een afname
wijst op een algehele verlaging van het pterinemetabolisme, hetgeen implicaties heeft
voor de synthese van NO en neurotransmitters zoals dopamine en serotonine. De
verschillende afwijkingen die gevonden zijn in pterines, NO en aminozuren zijn mogelijke
een biochemisch endofenotype van de verschillende affectieve stoornissen.
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Pteridines and affective disorders
Rocco Hoekstra, Durk Fekkes
Abstract
The pteridine tetrahydrobiopterin (BH4) is an essential cofactor in the biosynthesis of
dopamine, (nor)epinephrine, serotonin and nitric oxide (NO). Furthermore, BH4 has a
direct influence on release mechanisms of these neurotransmitters and on serotonin
receptor binding activity. 
The synthesis of BH4 is stimulated by interferon-gamma and hence there is a close
relationship with the immune system. In animal experiments it was also found that the
hypothalamus-pituitary-adrenal-axis influences the pteridine metabolism. In clinical
studies, so far, no evidence is found for this relationship.
A congenital biopterin deficiency results in atypical phenylketonuria with severe neuropsy-
chiatric symptoms. In several neurological diseases, like Parkinson's disease, decreased
levels of BH4 are found. 
Since 1984 there have been reports on decreased biopterin and increased neopterin levels
in urine and plasma of depressed patients. Conflicting results are also found however,
probably due to methodological problems. Up to now, oral administration of BH4 to
depressed patients has been performed by two investigators, which resulted in mostly
temporal clinical improvement. 
Understanding of biochemical mechanisms in which pteridines are involved may
contribute to our knowledge of the pathogenesis and treatment of affective disorders. This
article aims to give an overview of the relevant literature and warrant for further research
on this intriguing compound. 
Published in Acta Neuropsychiatrica 2002; 14: 120-126
 
Introduction
An aberrant metabolism of the monoamines norepinephrine, dopamine and serotonin in
the central nervous system has been hypothesized to be related to the pathophysiology of
affective disorders [1]. In the monoamine metabolism the pteridines, e.g. tetrahydro-
biopterin (BH4), play an important role. BH4 is a reduced pterine molecule, which acts as
the essential cofactor for the conversion of phenylalanine to tyrosine and the hydroxylation
of tyrosine and tryptophan. These conversions are the rate limiting steps in the formation
of serotonin, norepinephrine and dopamine [2,3] (figure 1). Independent of its cofactor-
role, BH4 has a direct influence on the release mechanism of these neurotransmitters [4,5]. 
These are facts from which a pivotal role for the pteridines in the pathogenesis of affective
disorders could be suggested. The aim of this review is to give an update of the relevant
literature in this field. We searched for review articles about pteridines in general, and for
original research articles about pteridines in relation to psychiatric disorders in specific. 
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Figure 1. 
Biosynthesis of tetrahydrobiopterin and its effect on the hydroxylation of phenylalanine,
tyrosine and tryptophan.
Biosynthesis
BH4 is synthesized de novo from guanosine triphosphate (GTP). GTP is converted to dihydro-
neopterin triphosphate and then by a series of tetrahydro intermediates to BH4. BH4 donates
an electron in the process of hydroxylation of phenylalanine, tyrosine or tryptophan, which
yields quinoid dihydrobiopterin. Cellular concentrations of BH4 are maintained by de novo
synthesis and a salvage mechanism that reduces quinoid dihydrobiopterin to BH4 by the
enzyme dihydropteridine reductase with NADH as a cofactor. Dihydroneopterin triphosphate
is secreted in the urine after oxidation to neopterin. BH4 is secreted in the urine with its
oxidative products dihydrobiopterin and biopterin [2,3,6] (figure 1).  Synthesis is not
dependent on dietary pterin, which is poorly absorbed from the gut [7].
Localization and function
BH4 is present in the liver, the gastrointestinal tract, the adrenal medulla, T-lymphocytes
and macrophages. In brain, the hypothalamus, pituitary gland and pineal gland contain
relatively large concentrations of BH4 [2,3]. Cerebral activity of BH4 seems to be related
mainly to the activity of tyrosine hydroxylase and to a lesser extent to that of tryptophan
hydroxylase. Thus, the influence on the catecholaminergic system seems to be more
important than the influence on the serotonergic system [5, 8-12].
The best investigated function of BH4 is the above mentioned action as a natural cofactor
of the aromatic amino acid hydroxylases, i.e. phenylalanine hydroxylase, tyrosine
hydroxylase and tryptophan hydroxylase [2]. Furthermore, BH4 is required as an obligatory
cofactor for the enzyme nitric oxide (NO)-synthase, which catalyses the synthesis of
citrulline and NO from arginine [2,13,14].
BH4 has also been suggested to act as a self-protecting factor for NO-toxicity [2].  For
example, in the endothelium activation of nitric oxide synthase, in the absence of BH4,
causes increased formation of oxygen-derived radicals impairing vascular tone [15-17]. 
In this article we will focus on the sparse literature concerning the functions of BH4 in
relation to psychiatric disorders.
Immunology
Pteridines are functionally closely related to the immune system [3]. Interferon-gamma,
which is produced and secreted by activated T-cells, stimulates GTP cyclohydrolase activity,
resulting in synthesis of pteridines.
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Neopterin is an established, validated marker of the activation of cell-mediated immunity
in biological processes. Neopterin detection is especially useful in screening for the
presence of viral infections or in the management of particularly HIV infection
[3,10,12,18]. Macrophages can secrete only neopterin and not biopterin because of the
absence of the enzyme 6-pyruvoyl-dihydropterin (PPH4) synthase (figure 1). Activation of
GTP cyclohydrolase in macrophages will therefore cause a large increase in the synthesis of
neopterin [3].
Whether evidence for immune activation can be found in affective disorders remains
debatable. Some groups did not find activated immune markers in depressed patients
[19,20]. Other groups reported on signs of an activated Inflammatory Response System,
like increased white blood cell count, monocytes, T-lymphocytes, prostaglandines and
cytokines [21]. The increased neopterin secretion found in some studies of depressed
patients is compatible with findings of an activated immune system in depression
[12,18,22,23].
Hypothalamus-pituitary-adrenal-axis    
The hypothalamus-pituitary-adrenal-axis seems to influence the pteridine metabolism. In
animal experiments it was found that glucocorticoids inhibit induction of nitric oxide
formation by direct influence on the enzyme NO synthase as well as by reducing the
availability of BH4 [24]. An activated HPA-axis, as often found in depressed patients, could
decrease the BH4 concentration and in this way affect the monoamine metabolism.
Furthermore, NO which is dependent on BH4 for its synthesis, plays a mediating role in the
HPA-axis [13].
Only in a small number of patients the relationship between pteridines and the HPA-axis is
studied. O'Toole reported no differences in neopterin concentration in 35 depressed
patients before and after the CRH and ACTH stimulation tests [25]. Garbutt also found no
differences in biopterin and neopterin concentrations in urine of 9 patients with major
depression before and after a dexamethason suppression test [26]. Further research should
focus on the link between biopterin in plasma and the HPA-axis in strictly selected patients. 
Experimental research
The effect of administration of BH4 on the concentration of several neurotransmitters is
studied in vitro. In samples of striatum and frontal cortex of rats, administration of BH4
caused an increase in the release of dopamine, serotonin and glutamate. The release of
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glutamate is probably influenced by the catecholaminergic system [27]. After adminis-
tration of BH4 in the ventricles of living rats, an increase in the concentrations of DOPA,
dopamine, 5-hydroxytryptophan and serotonin was seen in vitro after decapitation,
particularly in the diencephalon and the brainstem of rats [11]. 
Koshimura et al. also reported on an increase in dopamine release in striatum of rats after
administration of BH4, but concluded that this was not caused by increased synthesis [4].
In a comparable study Wolf et al. showed that BH4 causes increased release of serotonin,
probably by more influx of calcium or by increased sensibility of the release mechanism for
calcium. These effects of BH4 occur independently of its cofactor role for tryptophan
hydroxylase [5]. In rat brain a change in serotonin receptor binding activity was also seen
after peripheral administration of BH4 in the living rat. A post mortem increase in binding
activity of the 5-HT1a receptor in the hippocampus and decrease in the visual cortex was
seen. Binding of ketanserin to the 5-HT2 receptor increased in the striatum and the
hippocampus and decreased in the cerebellum and the visual cortex [28]. 
Diseases with changes in pteridine metabolism
A changed BH4 metabolism may lead to neurological and psychiatric symptoms. A
disturbed BH4 synthesis causes atypical phenylketonuria. About 2% of patients with
phenylketonuria show a BH4-deficiency [29]. Congenital biopterin deficiencies are the
consequence of various enzyme defects. For example, deficiencies of dihydropteridine
reductase and of 6-PPH4 synthase have been reported [29-31]. In case of BH4 deficiency
mostly changes have been found in the liver and in the brain, although a BH4 deficiency
solely in the liver has also been found [3]. It seems therefore plausible that a sole cerebral
manifestation is possible. Probably several neuropsychiatric diseases with low BH4 concen-
trations can be explained in this way. In the brain there seems to be heterogeneity of BH4
activity in monoamine-containing neurons [8,9]. Therefore, it is not expected that periph-
erally measured, changed BH4 values are specific for one disease.
In patients with congenital biopterin deficiency, decreased plasma and cerebrospinal fluid
(CSF) concentrations of serotonin, dopamine and their metabolites were found next to
hyperphenylalaninemia. Unlike patients with classical phenylketonuria a phenylalanine
restricted diet cannot prevent severe symptoms [9]. When substitution with the above-
mentioned neurotransmitters is not started in the first postnatal weeks, which is very
difficult, severe and progressive damage of the nervous system is seen. Clinical symptoms
may be microcephaly, irritability, poor head control, feeding and swallowing problems,
hypersalivation, temperature disturbance, truncal hypotonia and lethargy. Later signs
include rigidity, convulsions and progressive mental retardation [32].
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Decreased BH4 levels in CSF have been found in patients with Parkinson's disease, familial
dystonia and some other rare neurological diseases [33,34]. Besides, in patients with
Alzheimer's disease and other dementias lower biopterin levels were reported [35]. Kay et
al. reported that the decrease of biopterin in CSF was not correlated with ventricular
volume or with the severity of dementia, suggesting lowering of biopterin independent
from atrophy of brain tissue [36].
Pteridines and affective disorders
Because of their influence on the synthesis and release of several neurotransmitters, the
relationship between pteridines and affective disorders has been studied. In 1984 Blair
already reported on a link between biopterin and recurrent affective disorders. Patients
with a bipolar disorder, using lithium and being euthymic, had a significant decrease in
total biopterin excretion compared with healthy controls and patients with a unipolar
depression. It cannot be excluded that lithium is the cause of this lower excretion. On the
other hand, he also found reduced BH4 synthesis in post mortem temporal cortex samples
of four patients with a history of severe depression [37]. Coppen also found lowered
biopterin concentrations in the urine of depressed patients [38]. However, Hashimoto
reported an increase in total plasma biopterin levels in twelve patients with affective
disorders, depressive as well as hypomanic. The active compound BH4, however, was
decreased in depressed patients and increased in hypomanic patients. In patients with
schizophrenia or panic disorder BH4 levels were not different from those in normal controls
[39]. In a study of Anderson et al. it was shown that patients with a psychotic depression
and depressed patients responding to electroconvulsive therapy (ECT) had a significantly
higher urinary neopterin-biopterin (N-B) ratio compared to controls before starting ECT,
while a positive therapeutic response was associated with a reduction of the N-B ratio
towards control values [40]. A raised N-B ratio probably implies reduced availability of BH4
and hence less synthesis of serotonin, dopamine and norepinephrine [40]. Abou-Saleh et
al. measured urinary neopterin and biopterin in 48 patients with depression, fulfilling DSM-
III criteria,  before and after treatment with placebo, antidepressants, or ECT. Patients prior
to and post treatment had a significantly higher N-B ratio than control subjects and
besides, a significant correlation was observed between the N-B ratio and severity of
depression [41].
Our group has measured biopterin in plasma of 20 medication free patients, who had not
responded to antidepressants and therefore were indicated for ECT. Pretreatment
biopterin concentrations in these patients were decreased compared to normal controls.
After - in most of the times - successful ECT treatment plasma biopterin levels in psychotic
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depressed patients showed an increase [42].
However, some investigators found an increase in biopterin concentration in depressed
patients. Knapp, for example, observed an increase in plasma biopterin in 20 mild to
severely depressed patients with a history of alcohol abuse [43]. Duch and Garbutt found
an increase in urinary levels of biopterin in small groups of depressed patients [26,44].
Neopterin, the secretory metabolite of a precursor of BH4, is measured by Dunbar et al. in
plasma and urine of 26 depressed and 22 schizophrenic patients. These investigators
found a significantly increased level of this compound in plasma of depressed patients,
whereas no significant changes were seen in urine. The levels in schizophrenic patients
were comparable with those in normal controls [18]. Maes et al. and Matsuda et al. found
an increased serum neopterin concentration in depressed patients, while Bonaccorso
reported on an increase of this substance in urine [12,22,23]. O'Toole and our group found
no change in plasma neopterin in depressed patients compared to healthy controls
[25,42].
Methodological deficits may explain these seemingly contradictory results. Measurements
were often performed in urine samples and the symptomatology of the depressed patients
was not always well described. Maybe the spectrum of pathology, when using DSM
criteria, is too broad to find unequivocal results. Theoretically, using strictly selected
depressed patients, an increased plasma neopterin level, suggesting an activated immune
system, and a decreased plasma biopterin plasma level, leading to less biosynthesis of
serotonin and catecholamines, should be expected.
Therapy
In vitro BH4 administration yields the same effects at neurotransmitter level as does
standard antidepressant treatment [4,5,11,27,28]. Therefore, studying the effect of BH4
administration to depressed patients may be useful. Substantial amounts of BH4 can be
detected in cerebrospinal fluid when BH4 is administered orally or intravenously [45,46].
After peripheral administration of BH4 some positive clinical effects can be observed in
various neuropsychiatric disorders [47,48]. 
Curtius described in 1982 the effect of BH4 administration in three depressed patients and
two patients with Parkinson's disease. Two of the depressed patients, especially those with
so called inhibited endogenous depression, improved clinically after 4 to 5 hours and the
symptoms reappeared approximately 10 hours after the loading [49]. Fleischhacker did a
double-blind crossover trial with BH4 versus placebo in 8 therapy resistant depressed
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patients. Previous and hitherto ineffective medication was continued. One patient
improved after placebo. Another patient, who already used 5-hydroxytryptophan and
tranylcypromine showed a positive response on BH4, which lasted for 11 days. In four
patients signs of increased vigilance and drive were detected either by observation or in
clinical EEG analyses for 1 to 6 days [50]. 
These results suggest that BH4 indeed is important in the pathogenesis of depression. We
have not found any other reports in the literature on loading studies with BH4 in depressed
patients. 
Discussion
The pteridine metabolism plays an essential role in the biosynthesis of neurotransmitters,
known to be related to affective disorders, such as serotonin, norepinephrine and
dopamine [2]. Pteridines are functionally closely related to the cell-mediated immune
system [3]. The link with the hypothalamus-pituitary-adrenal-axis is less clear as yet [13].
Furthermore, pteridines seem to act as a protecting factor for NO-toxicity. The role of NO in
affective disorders is still unclear [13].
Although laboratory findings in animals and brain tissue point to an involvement of
pteridines in the pathogenesis of depression, and although this would fit in most of the
theories used for explaining depressive symptoms, so far contradictory results are reported
in depressed patients. Most clinical studies, using severe endogenous depressed patients,
point to a decrease in biopterin activity in depression [37-42]. The difference with biopterin
values in other psychiatric disorders, like schizophrenia and panic disorder, is remarkable
[39]. Probably this is indicative for a specific role of biopterin in depression. 
It is not yet clear if plasma or urine biopterin reflects cerebral activity and can be used as a
marker. In temporal cortex material of 4 patients with a history of severe depression less
biopterin synthesis was found [37], probably corresponding with lowered biopterin plasma
levels, found in depressed patients. In other diseases a decrease of biopterin in plasma as well
as in CSF has been described [35,36,51,52]. In a few depressed patients an indication for low
CSF biopterin or no change in CSF biopterin compared to healthy controls was found
[53,54,55]. We think plasma levels could be an indicator of central activity but because
pteridines are localized in many tissues, organic diseases can confound results easily.
Disorders like Parkinson's disease, dementia, neoplastic disorders and immunological distur-
bances, known to influence pteridine metabolism, should be detected precisely and excluded
in further studies. Furthermore results should be corrected for age, because there seems to be
an age-related increase in biopterin derivatives levels [7]. Plasma and urine samples should be
treated under standardized conditions, for example protected from light [18]. 
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The most obvious results in peripheral measures were found in severely depressed patients
[40-42]. Therefore, it seems necessary to include strictly selected patients with
homogenous symptomatology. The pteridine metabolism could especially be disturbed in
certain subpopulations, such as psychotic depressed patients or antidepressant resistant
patients. Biopterin may also be specifically related to a certain dimension of depressive
behaviour.
Peripheral values of neopterin seem to be less specific than biopterin. Even more conflicting
results are found when neopterin is studied in depressed patients. Probably too much
factors can influence neopterin, specifically age and somatic comorbidity.
A more dynamic approach, by interacting with several neuroendocrine systems through
administration of biopterin, could give most interesting information. By studying the effect
of biopterin on neurotransmitters, immunological parameters and the HPA-axis in vivo,
much more information on the role of this intriguing compound in the pathophysiology of
affective disorders will be obtained.  
Conclusion
The pteridines seem to play an important role in affective disorders. There is still a big gap
between theories about depression and in vitro laboratory findings on the one hand and
clinical results on the other. This should be overcome by strict selection of patients and
standardization of laboratory measurements. Probably biopterin can act as a marker for
the depressive state in certain subpopulations. Results of biopterin loading studies could
have therapeutic implications. 
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